[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1473
1. Safioleas MC, Moulakakis KG, Stamatakos M, Kountouras J, Lygidakis NJ: Local recurrence following curative low anterior resection for rectal carcinoma. Hepatogastroenterology; 2005 Jan-Feb;52(61):94-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We attempted to identify possible factors affecting the frequency of local recurrence, focusing on the clearance of the tumor and the margin of resection.
  • The proximal and distal margins of the tumor were measured before fixing for permanent sections.
  • RESULTS: Analysis by distance of the tumor from the anal verge revealed that 5 out of 33 patients (15.15%) from the upper rectal group and 7 out of 19 patients (36.8%) from the mid rectal group developed local recurrences (36.8% vs. 15.15% P=0.0369).
  • CONCLUSIONS: Tumors located in the upper portion of the rectum presented a minor tendency for local recurrence compared to tumors located in the middle of the rectum.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / surgery. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / mortality. Rectal Neoplasms / mortality. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Survival Rate. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783003.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R: Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology; 2010;220(1):77-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
  • Imatinib has become the standard of care in other cancers with KIT mutations such as gastrointestinal stromal tumors.
  • We report here on one of our patients with KIT-activating mutation in metastatic anal mucosal melanoma, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996579.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 18
  •  go-up   go-down


3. Petry KU: [What does HPV vaccination mean for gynecologic cancer screening?]. Hautarzt; 2007 Jun;58(6):501-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papilloma viruses (HPV) of the high-risk type cause almost all cervical carcinomas and some other anogenital tumors.
  • Current studies suggest that 70-80% of high-grade cervical neoplasias can be avoided, as well as other vaginal, vulvar, and anal neoplasias.
  • [MeSH-major] Gynecology / methods. Mass Screening / methods. Papillomavirus Infections / diagnosis. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines / therapeutic use. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / prevention & control


6. Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J, Pan QJ: ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol; 2010 Feb;32(1):45-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystoscopy with histologic diagnosis was used as the gold standard for diagnosis.
  • RESULTS: Of 169 inpatients, 135 cases had histologic diagnoses, including 93 cases of UC with primary tumors in 68 and recurrent tumors in 25, 26 cases of other urologic malignancies and 16 cases of benign urologic lesions.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701087.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


7. Zhao G, Peery RB, Yingling JM: Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase. Anal Biochem; 2007 Jan 15;360(2):196-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, the inhibition of this signaling pathway represents a promising therapeutic approach for the discovery of novel anticancer agents by destabilizing the progression of solid tumors via abrogating tumor-induced angiogenesis.

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141171.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 0 / Phosphates; 0 / Vascular Endothelial Growth Factor A; 42Z2K6ZL8P / Manganese; 61D2G4IYVH / Adenosine Diphosphate; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; I38ZP9992A / Magnesium
  •  go-up   go-down


8. Matsumura K, Opiekun M, Oka H, Vachani A, Albelda SM, Yamazaki K, Beauchamp GK: Urinary volatile compounds as biomarkers for lung cancer: a proof of principle study using odor signatures in mouse models of lung cancer. PLoS One; 2010;5(1):e8819
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A potential strategy for diagnosing lung cancer, the leading cause of cancer-related death, is to identify metabolic signatures (biomarkers) of the disease.
  • Sensor mice could be trained to discriminate between odors of mice with and without experimental tumors demonstrating that volatile odorants are sufficient to identify tumor-bearing mice.
  • Consistent with this result, chemical analyses of urinary volatiles demonstrated that the amounts of several compounds were dramatically different between tumor and control mice.
  • Using principal component analysis and supervised machine-learning, we accurately discriminated between tumor and control groups, a result that was cross validated with novel test groups.
  • Although there were shared differences between experimental and control animals in the two tumor models, we also found chemical differences between these models, demonstrating tumor-based specificity.
  • The success of these studies provides a novel proof-of-principle demonstration of lung tumor diagnosis through urinary volatile odorants.
  • [MeSH-major] Biomarkers, Tumor / urine. Disease Models, Animal. Lung Neoplasms / urine. Odors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Lung Cancer. 2010 Feb;67(2):227-31 [19409642.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5612-5 [11929982.001]
  • [Cites] Nat Rev Neurosci. 2003 Jul;4(7):551-62 [12838330.001]
  • [Cites] Nat Rev Microbiol. 2004 Feb;2(2):161-6 [15040263.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):712 [15388612.001]
  • [Cites] Clin Chem. 1981 Jun;27(6):789-97 [7016368.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Sep;78(9):5817-20 [6946517.001]
  • [Cites] Arch Toxicol. 1986 Apr;58(4):229-34 [3718225.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Genes Dev. 2005 Mar 15;19(6):643-64 [15769940.001]
  • [Cites] Anal Chem. 2005 Apr 15;77(8):2348-61 [15828767.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8379-87 [16166316.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):845-56 [16239904.001]
  • [Cites] Integr Cancer Ther. 2006 Mar;5(1):30-9 [16484712.001]
  • [Cites] Trends Neurosci. 2006 Nov;29(11):604-9 [16904761.001]
  • [Cites] Nat Biotechnol. 2006 Dec;24(12):1565-7 [17160063.001]
  • [Cites] JAMA. 2007 Mar 7;297(9):953-61 [17341709.001]
  • [Cites] Curr Med Chem. 2007;14(9):987-95 [17439398.001]
  • [Cites] Nat Chem Biol. 2007 Jun;3(6):325-30 [17486045.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):249-55 [17534168.001]
  • [Cites] Clin Transl Oncol. 2007 Jun;9(6):364-8 [17594950.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):835-44 [17599760.001]
  • [Cites] Science. 2007 Aug 17;317(5840):953-7 [17702944.001]
  • [Cites] AJR Am J Roentgenol. 2008 Mar;190(3):755-61 [18287449.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1118-28 [18337602.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):548-52 [18385728.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):580-9 [18385732.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):758-60 [18388886.001]
  • [Cites] Radiology. 2008 May;247(2):400-8 [18430874.001]
  • [Cites] J Altern Complement Med. 2008 Jan-Feb;14(1):61-7 [18199013.001]
  • [Cites] Science. 2008 Aug 22;321(5892):1092-5 [18719286.001]
  • [Cites] PLoS One. 2008;3(9):e3139 [18769554.001]
  • [Cites] PLoS One. 2008;3(10):e3591 [18974891.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2008 Nov;12(6):707-13 [19000949.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):419-26 [19331181.001]
  • [Cites] Lung Cancer. 2009 May;64(2):166-70 [18834643.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9249-54 [11459940.001]
  • (PMID = 20111698.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2811722
  •  go-up   go-down


9. Powlesland AS, Hitchen PG, Parry S, Graham SA, Barrio MM, Elola MT, Mordoh J, Dell A, Drickamer K, Taylor ME: Targeted glycoproteomic identification of cancer cell glycosylation. Glycobiology; 2009 Aug;19(8):899-909
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glycan array screening demonstrated that the carbohydrate-recognition domain of GalMBP selectively binds common groups of tumor-associated glycans, including Lewis-type structures and T antigen, suggesting that engineered glycan-binding proteins such as GalMBP represent novel tools for the characterization of glycoproteins bearing tumor-associated glycans.
  • The pool of ligands was found to include the target ligands for anti-CD15 antibodies, which are commonly used to detect Lewis(x) antigen on tumors, and for the endothelial scavenger receptor C-type lectin, which may be involved in tumor metastasis through interactions with this antigen.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] Glycobiology. 2009 Apr;19(4):437-50 [19129245.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2584-8 [10825125.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):355-64 [11547903.001]
  • [Cites] Glycoconj J. 2004;19(7-9):543-9 [14758078.001]
  • [Cites] J Immunol. 1981 May;126(5):1966-9 [7217675.001]
  • [Cites] Anal Biochem. 1981 Apr;112(2):195-203 [6266278.001]
  • [Cites] Cancer Res. 1986 Mar;46(3):1478-84 [2417704.001]
  • [Cites] Am J Pathol. 1986 Jun;123(3):508-19 [3717303.001]
  • [Cites] Methods Enzymol. 1994;230:108-32 [8139492.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15512-9 [8195195.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1995 Apr;17(3):151-60 [7613641.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6679-85 [8636086.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] Biochem J. 1997 Jul 15;325 ( Pt 2):391-400 [9230118.001]
  • [Cites] Glycoconj J. 1997 Aug;14(5):569-76 [9298689.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30 [9689079.001]
  • [Cites] Immunol Rev. 1998 Jun;163:19-34 [9700499.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):371-5 [9892640.001]
  • [Cites] J Biol Chem. 1999 Jan 29;274(5):3009-16 [9915839.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3580-9 [9920905.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 7;262(3):720-5 [10471392.001]
  • [Cites] Curr Opin Struct Biol. 1999 Oct;9(5):585-90 [10508765.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):477-88 [15931257.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22993-9 [15845541.001]
  • [Cites] Immunol Cell Biol. 2005 Aug;83(4):429-39 [16033539.001]
  • [Cites] Glycobiology. 2006 Aug;16(8):1C-7C [16670103.001]
  • [Cites] J Biol Chem. 2006 Jul 21;281(29):20440-9 [16682406.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(2):161-74 [16850248.001]
  • [Cites] J Biol Chem. 2007 Jun 8;282(23):17250-8 [17420244.001]
  • [Cites] J Mol Biol. 2007 Dec 14;374(5):1224-36 [17996897.001]
  • [Cites] J Membr Biol. 2000 Feb 1;173(3):165-77 [10667913.001]
  • (PMID = 19433864.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 075565; United States / NIGMS NIH HHS / GM / GM62116; United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD98; 0 / Ligands; 0 / Mannose-Binding Lectin; 0 / Mucin-1; 0 / Polysaccharides; X2RN3Q8DNE / Galactose
  • [Other-IDs] NLM/ PMC2704901
  •  go-up   go-down


11. Cunha IW, Carvalho KC, Martins WK, Marques SM, Muto NH, Falzoni R, Rocha RM, Aguiar S, Simoes AC, Fahham L, Neves EJ, Soares FA, Reis LF: Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol; 2010 Feb;3(1):23-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors.
  • Soft tissue tumors represent a group of neoplasia with different histologic and biological presentations varying from benign, locally confined to very aggressive and metastatic tumors.
  • The understanding of these molecular alterations mechanism will be critical to discriminate patients who need systemic treatment from those that can be treated only locally and could also guide the development of new drugs' against this tumors.
  • Using 102 tumor samples representing a large spectrum of these tumors, we performed expression profiling and defined differentially expression genes that are likely to be involved in tumors that are locally aggressive and in tumors with metastatic potential.
  • These genes are mainly related to cell-cell and cell-extracellular matrix interactions and cell proliferation and might represent helpful tools for a more precise classification and diagnosis as well as potential drug targets.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):1063-9 [15252314.001]
  • [Cites] Cell Prolif. 2004 Apr;37(2):161-75 [15030550.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7201-4 [15492233.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):611-22 [15548371.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2192-201 [15914641.001]
  • [Cites] J Cell Sci. 2005 Sep 1;118(Pt 17):4049-57 [16129888.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):487-98 [16428491.001]
  • [Cites] Liver Int. 2006 May;26(4):424-32 [16629645.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 1;168(1):30-5 [16772118.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):5-24 [16773180.001]
  • [Cites] Biochem J. 2007 Jan 15;401(2):447-57 [16981854.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):404-10 [17122636.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):240-6 [17255769.001]
  • [Cites] Cell Signal. 2007 Jun;19(6):1315-27 [17336041.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13759-68 [17337440.001]
  • [Cites] BMC Genomics. 2007;8:73 [17359542.001]
  • [Cites] J Biol Chem. 2007 Jun 1;282(22):16401-12 [17412687.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):955-65 [17450526.001]
  • [Cites] Free Radic Biol Med. 2007 Jun 1;42(11):1704-14 [17462538.001]
  • [Cites] J Toxicol Environ Health A. 2007 Jun;70(11):876-84 [17479401.001]
  • [Cites] J Toxicol Environ Health A. 2007 Jun;70(11):885-94 [17479402.001]
  • [Cites] J Toxicol Environ Health A. 2007 Jun;70(11):895-900 [17479403.001]
  • [Cites] Stem Cells. 2007 Dec;25(12):3121-32 [17717065.001]
  • [Cites] Semin Thromb Hemost. 2007 Oct;33(7):667-72 [18000793.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1734-43 [18347174.001]
  • [Cites] N Engl J Med. 2008 Dec 25;359(26):2814-23 [19109576.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Cytotechnology. 1996;19(3):253-6 [8862015.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1956-66 [9528767.001]
  • [Cites] Oncogene. 1998 Oct 22;17(16):2039-45 [9798675.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):484-5 [11831227.001]
  • [Cites] Circ Res. 2002 Mar 22;90(5):506-8 [11909813.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5859-66 [12384549.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1587-95 [12414507.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):549-58 [12827608.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4167-73 [12874022.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Anal Biochem. 2003 Oct 15;321(2):244-51 [14511690.001]
  • [Cites] Clin Exp Metastasis. 2003;20(7):665-74 [14669798.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):235-40 [14685255.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):516-23 [14696115.001]
  • [Cites] Ai Zheng. 2004 Mar;23(3):264-8 [15025954.001]
  • [Cites] Oncogene. 2004 Nov 25;23(55):8997-9006 [15467746.001]
  • (PMID = 20165692.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2822450
  •  go-up   go-down


12. Oršolić N, Benković V, Lisičić D, Dikić D, Erhardt J, Knežević AH: Protective effects of propolis and related polyphenolic/flavonoid compounds against toxicity induced by irinotecan. Med Oncol; 2010 Dec;27(4):1346-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was carried out to find whether propolis preparations and related flavonoids (quercetin, naringin) might enhance irinotecan-induced cytotoxicity to tumor cells in mice bearing Ehrlich ascites tumors (EAT) while protecting normal blood, liver, and kidney cells.
  • Irinotecan was administered ip at dose of 50 mg kg(-1) on days 3, 4, and 5 after tumor cell inoculation.
  • However, when mice were pre-treated with test components prior to irinotecan, the frequencies of irinotecan-induced micronuclei (MN) was decreased but in mice bearing tumor QU and EEP increased number of micronucleated cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / toxicity. Camptothecin / analogs & derivatives. Carcinoma, Ehrlich Tumor / drug therapy. Flavonoids / therapeutic use. Immunologic Factors / therapeutic use. Phenols / therapeutic use. Propolis / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr. 2004 Nov;134(11):3201S-3204S [15514307.001]
  • [Cites] Exp Cell Res. 1973 Mar 15;77(1):323-34 [4570355.001]
  • [Cites] Environ Health Perspect. 1994 Jan;102 Suppl 1:49-52 [8187724.001]
  • [Cites] Antioxid Redox Signal. 2002 Feb;4(1):97-104 [11970847.001]
  • [Cites] Drugs Exp Clin Res. 1987;13(10):593-9 [3428123.001]
  • [Cites] Phytochem Anal. 2004 Jul-Aug;15(4):235-40 [15311843.001]
  • [Cites] J Ethnopharmacol. 2007 Aug 15;113(1):1-14 [17580109.001]
  • [Cites] Xenobiotica. 1994 Jul;24(7):689-99 [7975732.001]
  • [Cites] J Am Coll Nutr. 2001 Dec;20(6):628-36 [11771679.001]
  • [Cites] Altern Med Rev. 2000 Apr;5(2):152-63 [10767670.001]
  • [Cites] Semin Oncol. 1992 Dec;19(6 Suppl 13):3-9 [1492225.001]
  • [Cites] Integr Cancer Ther. 2004 Dec;3(4):333-41 [15523104.001]
  • [Cites] Evid Based Complement Alternat Med. 2004 Sep 1;1(2):175-185 [15480443.001]
  • [Cites] Adv Nephrol Necker Hosp. 1988;17:175-218 [3124539.001]
  • [Cites] Exp Mol Pathol. 1995 Jun;62(3):190-8 [8612723.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):461-8 [12216075.001]
  • [Cites] Toxicology. 2004 Feb 15;195(2-3):87-95 [14751666.001]
  • [Cites] Braz J Med Biol Res. 2002 Jul;35(7):819-22 [12131922.001]
  • [Cites] Acta Pharm. 2003 Dec;53(4):275-85 [14769234.001]
  • [Cites] Food Chem Toxicol. 2002 Jul;40(7):941-7 [12065216.001]
  • [Cites] Planta Med. 2006 Jan;72(1):20-7 [16450291.001]
  • [Cites] Biol Pharm Bull. 2005 Feb;28(2):364-6 [15684501.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 16;72 (8):1010-21 [16934226.001]
  • [Cites] Biomed Pharmacother. 2007 Jun;61(5):292-7 [17412551.001]
  • [Cites] Biol Pharm Bull. 2005 Apr;28(4):694-700 [15802812.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1606-14 [16533788.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2005 Jan;140(1):69-78 [15792625.001]
  • [Cites] J Nat Prod. 1995 Feb;58(2):217-25 [7769390.001]
  • [Cites] Biochem J. 2004 Dec 15;384(Pt 3):527-41 [15312049.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 Jun;67(6):1215-22 [12843645.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Oct;17(5):553-62 [12470425.001]
  • [Cites] Mutat Res. 1997 Jun 13;391(1-2):87-9 [9219552.001]
  • [Cites] Inflammation. 1990 Feb;14(1):125-32 [2323805.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5841-4 [2168283.001]
  • [Cites] Semin Oncol. 1982 Mar;9(1):95-102 [7071611.001]
  • [Cites] Biomed Pharmacother. 2005 Dec;59(10):561-70 [16202559.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34 Suppl:S69-75 [8070031.001]
  • [Cites] Acta Pharm. 2004 Mar;54(1):65-72 [15050046.001]
  • [Cites] Am J Clin Nutr. 1998 Dec;68(6 Suppl):1375S-1379S [9848502.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2006 Jul;143(3):349-54 [16720105.001]
  • [Cites] Cell Immunol. 1977 Mar 1;29(1):86-95 [849607.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34 Suppl:S64-8 [8070030.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Dec;299(3):915-20 [11714876.001]
  • [Cites] Lancet. 1993 Oct 23;342(8878):1007-11 [8105262.001]
  • (PMID = 20013318.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Immunologic Factors; 0 / Phenols; 0H43101T0J / irinotecan; 9009-62-5 / Propolis; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


13. Biragyn A, Schiavo R, Olkhanud P, Sumitomo K, King A, McCain M, Indig FE, Almanzar G, Baatar D: Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity. J Immunol; 2007 Jul 15;179(2):1381-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity.
  • Despite its potency, the wider use of immunotherapy for B cell malignancies is hampered by the lack of well-defined tumor-specific Ags.
  • In this study, we demonstrate that an evolutionarily conserved 37-kDa immature laminin receptor protein (OFA-iLRP), a nonimmunogenic embryonic Ag expressed by a variety of tumors, is rendered immunogenic if targeted to the APCs using the CCR6 ligands MIP3alpha/CCL20 and mDF2beta.
  • The CCR6 targeting facilitated efficient Ag cross-presentation and induction of tumor-neutralizing CTLs.
  • [MeSH-major] Antigens, Neoplasm / immunology. CD8-Positive T-Lymphocytes / immunology. Cancer Vaccines / therapeutic use. Lymphoma, B-Cell / therapy. Receptors, Chemokine / immunology. Receptors, Laminin / immunology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Rev. 1999 Aug;170:115-26 [10566146.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4597-605 [16514063.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):769-79 [11560993.001]
  • [Cites] J Immunol. 2001 Dec 1;167(11):6644-53 [11714836.001]
  • [Cites] Immunity. 2001 Dec;15(6):971-83 [11754818.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2422-9 [12193710.001]
  • [Cites] Haematologica. 2002 Sep;87(9):989-1001 [12217812.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13020-5 [12232042.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1025-9 [12411706.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2127-33 [12727829.001]
  • [Cites] Int J Hematol. 2003 Jun;77(5):444-55 [12841382.001]
  • [Cites] Mol Biol Cell. 2003 Oct;14(10):4221-9 [12937274.001]
  • [Cites] Nat Immunol. 2003 Nov;4(11):1065-73 [14566337.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4416-23 [12869512.001]
  • [Cites] J Leukoc Biol. 2004 Jul;76(1):77-85 [15075363.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1961-9 [15191951.001]
  • [Cites] J Immunol. 1979 Feb;122(2):549-54 [310843.001]
  • [Cites] J Biol Chem. 1986 Aug 25;261(24):11398-403 [2426273.001]
  • [Cites] J Immunol. 1987 Feb 15;138(4):1289-96 [3492546.001]
  • [Cites] EMBO J. 1989 Jul;8(7):1947-52 [2792076.001]
  • [Cites] Biochemistry. 1989 Sep 5;28(18):7476-86 [2531008.001]
  • [Cites] Annu Rev Immunol. 1990;8:303-33 [1693082.001]
  • [Cites] Biochem Biophys Res Commun. 1991 May 31;177(1):177-83 [1828340.001]
  • [Cites] J Biol Chem. 1991 Oct 25;266(30):20440-6 [1834645.001]
  • [Cites] Anal Biochem. 1992 Sep;205(2):263-70 [1332541.001]
  • [Cites] Immunol Rev. 1995 Jun;145:211-28 [7590827.001]
  • [Cites] Nat Med. 1996 Sep;2(9):1038-41 [8782465.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):373-86 [9670049.001]
  • [Cites] Immunol Today. 1998 Sep;19(9):405-8 [9745203.001]
  • [Cites] J Immunother. 1998 Sep;21(5):323-39 [9789195.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1281-6 [9809552.001]
  • [Cites] Nat Biotechnol. 1999 Mar;17(3):253-8 [10096292.001]
  • [Cites] Eur J Immunol. 1999 May;29(5):1617-25 [10359116.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10326-31 [10468607.001]
  • [Cites] Nat Med. 1999 Oct;5(10):1171-7 [10502821.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):88-93 [15744305.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10987-92 [16037207.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):2844-56 [16493041.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6935-44 [16709854.001]
  • [Cites] Anticancer Res. 1999 Nov-Dec;19(6C):5535-42 [10697612.001]
  • (PMID = 17617631.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AG000770-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CCL20 protein, mouse; 0 / CCR6 protein, mouse; 0 / Cancer Vaccines; 0 / Chemokine CCL20; 0 / Chemokines, CC; 0 / Macrophage Inflammatory Proteins; 0 / Receptors, CCR6; 0 / Receptors, Chemokine; 0 / Receptors, Laminin; 0 / oncofetal antigens
  • [Other-IDs] NLM/ NIHMS44868; NLM/ PMC2365706
  •  go-up   go-down


1
Advertisement
4. Iesalnieks I, Gaertner WB, Glass H, Strauch U, Hipp M, Agha A, Schlitt HJ: Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis; 2010 Oct;16(10):1643-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma in Crohn's disease.
  • BACKGROUND: Adenocarcinoma arising from perianal fistulae in patients with Crohn's disease (CD) is rare.
  • We present 6 patients with CD and fistula-associated anal adenocarcinoma (FAAA) and a systematic review of published series.
  • The average age at time of diagnosis was 45.5 years.
  • Four patients died with metastatic disease, 1 is alive with pelvic recurrence at 55 months, and 1 is alive without evidence of disease at 19 months follow-up.
  • Mean delay of cancer diagnosis was 11 months.
  • Thirteen of 15 patients with node-positive tumors died with recurrent disease following surgery.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / etiology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate


15. Bernet A, Mazelin L, Coissieux MM, Gadot N, Ackerman SL, Scoazec JY, Mehlen P: Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies. Gastroenterology; 2007 Dec;133(6):1840-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies.
  • Such a trait has been hypothesized to confer a tumor-suppressor activity.
  • Indeed, cells harboring these receptors are thought to be dependent on ligand availability for their survival, thereby inhibiting uncontrolled tumor cell proliferation.
  • We investigate here whether UNC5C acts as a tumor suppressor in colorectal malignancies.
  • Intestinal tumor progression was monitored in mice bearing both UNC5C and APC1638N mutations, and apoptosis was measured in intestinal tumors developed in UNC5C/APC1638N mutant mice.
  • Moreover, in mice, inactivation of UNC5C is associated with increased intestinal tumor progression and a decrease in tumor cell apoptosis.
  • CONCLUSIONS: The loss of UNC5C expression observed in human colorectal cancer is a selective advantage for tumor progression, in agreement with the dependence receptor hypothesis.
  • Thus, the UNC5C dependence receptor is a tumor suppressor that regulates sporadic colorectal cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2003 May 9;278(19):17483-90 [12598531.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4173-8 [12655055.001]
  • [Cites] Cancer Lett. 2004 Jan 8;203(1):25-33 [14670614.001]
  • [Cites] Apoptosis. 2004 Jan;9(1):37-49 [14739597.001]
  • [Cites] Cell Mol Life Sci. 2004 Aug;61(15):1854-66 [15289929.001]
  • [Cites] Nat Cell Biol. 2004 Aug;6(8):749-55 [15258591.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3420-8 [15310786.001]
  • [Cites] Nature. 2004 Sep 2;431(7004):80-4 [15343335.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Science. 1993 Jul 16;261(5119):345-8 [8332899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8969-73 [8090754.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cell. 1996 Oct 18;87(2):175-85 [8861902.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):796-804 [9126737.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):838-42 [9126743.001]
  • [Cites] Cell. 1998 Mar 6;92(5):645-56 [9506519.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):801-4 [9796814.001]
  • [Cites] Cell. 1999 Jun 25;97(7):927-41 [10399920.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):179-86 [15510105.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] EMBO J. 2005 Mar 23;24(6):1192-201 [15729359.001]
  • [Cites] Cell Death Differ. 2005 Aug;12(8):1031-43 [16015380.001]
  • [Cites] Cell Mol Life Sci. 2005 Nov;62(22):2599-616 [16158190.001]
  • [Cites] Science. 2003 Aug 8;301(5634):843-6 [12907805.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1745-50 [10561211.001]
  • [Cites] Cell. 1999 Nov 24;99(5):451-4 [10589672.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):4056-63 [10921886.001]
  • [Cites] EMBO J. 2001 Jun 1;20(11):2715-22 [11387206.001]
  • [Cites] J Cell Biol. 2001 Oct 29;155(3):459-70 [11684710.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):552-6 [11932749.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Biotechniques. 2002 Apr;32(4):776-8, 780, 782 [11962599.001]
  • [Cites] Nature. 2002 May 23;417(6887):443-7 [11986622.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):306-15 [12471613.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Nat Cell Biol. 2003 Mar;5(3):216-23 [12598906.001]
  • [CommentIn] Gastroenterology. 2007 Dec;133(6):2045-9 [18054576.001]
  • (PMID = 17967459.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS45093; United States / NINDS NIH HHS / NS / R01 NS045093-05; United States / NINDS NIH HHS / NS / NS045093-02; United States / NINDS NIH HHS / NS / R01 NS045093-02; United States / NINDS NIH HHS / NS / NS045093-03; United States / NINDS NIH HHS / NS / R01 NS045093; United States / NINDS NIH HHS / NS / R01 NS045093-01; United States / NINDS NIH HHS / NS / R01 NS045093-04; United States / NINDS NIH HHS / NS / NS045093-04; United States / NINDS NIH HHS / NS / R01 NS045093-03; United States / NINDS NIH HHS / NS / NS045093-01; United States / NINDS NIH HHS / NS / NS045093-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / UNC5C protein, human
  • [Other-IDs] NLM/ NIHMS35783; NLM/ PMC2211510
  •  go-up   go-down


16. Kim TH, Chen Y, Mount CW, Gombotz WR, Li X, Pun SH: Evaluation of temperature-sensitive, indocyanine green-encapsulating micelles for noninvasive near-infrared tumor imaging. Pharm Res; 2010 Sep;27(9):1900-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of temperature-sensitive, indocyanine green-encapsulating micelles for noninvasive near-infrared tumor imaging.
  • PURPOSE: Indocyanine green (ICG), an FDA-approved near infrared (NIR) dye, has potential application as a contrast agent for tumor detection.
  • The plasma clearance kinetics and biodistribution of ICG-loaded micelles was also determined after intravenous delivery to CT-26 colon carcinoma tumor-bearing mice, and NIR whole-body imaging was performed for tumor detection.
  • Solid tumors in mice were specifically visualized after intravenous administration of ICG-loaded micelles.
  • CONCLUSIONS: These materials are therefore promising formulations for noninvasive NIR tumor imaging applications.
  • [MeSH-major] Contrast Media / chemistry. Drug Carriers / chemistry. Indocyanine Green / chemistry. Neoplasms / diagnosis. Poloxamer / chemistry. Spectroscopy, Near-Infrared / methods

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Sci. 1961 Aug;21:43-57 [13689739.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6596-601 [18445654.001]
  • [Cites] Br J Ophthalmol. 2008 Feb;92(2):276-80 [18227207.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Jun 14;177(2):861-6 [2049107.001]
  • [Cites] Surgery. 2008 Jul;144(1):39-48 [18571583.001]
  • [Cites] Nat Nanotechnol. 2007 Dec;2(12):751-60 [18654426.001]
  • [Cites] Exp Biol Med (Maywood). 2009 Feb;234(2):123-31 [19064945.001]
  • [Cites] Photochem Photobiol Sci. 2003 Feb;2(2):124-9 [12664972.001]
  • [Cites] Curr Opin Ophthalmol. 1995 Jun;6(3):25-32 [10151085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2767-72 [10706610.001]
  • [Cites] Langmuir. 2008 May 20;24(10):5213-7 [18257595.001]
  • [Cites] J Control Release. 2006 May 1;112(1):15-25 [16515818.001]
  • [Cites] Biomacromolecules. 2007 Feb;8(2):650-6 [17291088.001]
  • [Cites] Curr Opin Biotechnol. 2007 Feb;18(1):17-25 [17234399.001]
  • [Cites] Mol Pharm. 2009 Mar-Apr;6(2):480-91 [19228053.001]
  • [Cites] J Pharm Sci. 2003 Oct;92(10):2090-7 [14502548.001]
  • [Cites] Int J Pharm. 2008 Oct 1;362(1-2):197-200 [18586076.001]
  • [Cites] J Biomed Opt. 2007 Jul-Aug;12(4):044020 [17867824.001]
  • [Cites] Photomed Laser Surg. 2006 Aug;24(4):514-21 [16942434.001]
  • [Cites] Anesthesiology. 2007 Mar;106(3):491-8 [17325507.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7870-5 [14633715.001]
  • [Cites] J Photochem Photobiol B. 2004 Mar 19;74(1):29-38 [15043844.001]
  • [Cites] Anal Chem. 1986 Nov;58(13):2649-53 [3813009.001]
  • [Cites] J Control Release. 2002 Aug 21;82(2-3):189-212 [12175737.001]
  • [Cites] Photochem Photobiol. 2000 Sep;72(3):392-8 [10989611.001]
  • [Cites] Int J Pharm. 2006 Feb 3;308(1-2):200-4 [16386861.001]
  • [Cites] J Control Release. 2001 Jan 29;70(1-2):1-20 [11166403.001]
  • [Cites] Med Phys. 2003 Jun;30(6):1039-47 [12852527.001]
  • [Cites] J Control Release. 2006 Oct 27;115(3):251-8 [17045355.001]
  • [Cites] Pharm Res. 2008 Jan;25(1):55-71 [17551809.001]
  • [Cites] Basic Res Cardiol. 2008 Mar;103(2):144-51 [18324370.001]
  • [Cites] J Control Release. 2000 Aug 10;68(2):167-74 [10925125.001]
  • [Cites] Surv Ophthalmol. 2000 Jul-Aug;45(1):15-27 [10946079.001]
  • [Cites] J Control Release. 2008 Sep 10;130(2):98-106 [18534704.001]
  • [Cites] J Biomed Opt. 2008 Jan-Feb;13(1):014025 [18315383.001]
  • [Cites] J Control Release. 2004 Dec 10;100(3):389-97 [15567504.001]
  • [Cites] Langmuir. 2006 Feb 14;22(4):1758-62 [16460102.001]
  • [Cites] Mol Pharm. 2009 Sep-Oct;6(5):1321-32 [19799463.001]
  • [Cites] ACS Nano. 2008 Oct 28;2(10):2075-84 [19206454.001]
  • [Cites] J Pharm Sci. 1996 Sep;85(9):915-9 [8877878.001]
  • [Cites] J Photochem Photobiol B. 1997 Apr;38(2-3):178-83 [9203378.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 29;104(22):9266-71 [17517614.001]
  • [Cites] Photochem Photobiol. 2000 Mar;71(3):347-50 [10732454.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Jun 15;57(8):1087-108 [15908041.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3752-6 [7641188.001]
  • (PMID = 20568000.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120480
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CG32663 protein, Drosophila; 0 / Contrast Media; 0 / Drosophila Proteins; 0 / Drug Carriers; 0 / Micelles; 106392-12-5 / Poloxamer; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


17. Elgaili EM, Abuidris DO, Rahman M, Michalek AM, Mohammed SI: Breast cancer burden in central Sudan. Int J Womens Health; 2010;2:77-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer is a worldwide disease resulting in many deaths.
  • Although breast cancer incidence is lower in Sub-Saharan African countries than in developed countries, African women are more likely than women in the developed world to be diagnosed at later stages of the disease and, thus, are more likely to die from it.
  • This descriptive study was undertaken to shed light on the type, stage and age distribution of breast cancer at diagnosis in women living in central Sudan encompassing al-Gezira, Blue Nile, White Nile, and Sennar States.
  • Invasive ductal carcinoma was the most common pathology (82%) and women presenting with stage III or higher tumors that had already metastasized, while ductal carcinoma in situ was the least prevalent (0.5%) finding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21072300.001).
  • [ISSN] 1179-1411
  • [Journal-full-title] International journal of women's health
  • [ISO-abbreviation] Int J Womens Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2971742
  • [Keywords] NOTNLM ; Africa / epidemiology / estrogen receptor / female breast cancer / progesterone receptor
  •  go-up   go-down


18. Mitra AP, Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH, Worzel WP: The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer; 2006 Jun 16;6:159
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study included primary bladder tumor tissues from 60 patients across different stages and 5 control tissues of normal urothelium.
  • Quantitative expression profiling was performed for a panel of 70 genes using standardized competitive RT-PCR and the expression values of the training set samples were run through an iterative machine learning process called genetic programming that employed an N-fold cross validation technique to generate classifier rules of limited complexity.
  • Additionally, the motifs showed CDK8 to be lower relative to ICAM1, and ANXA5 to be relatively high by itself in node positive tumors.
  • CONCLUSION: Our study demonstrates the use of standardized quantitative gene expression values from primary bladder tumor tissues as inputs in a genetic programming system to generate classifier rules for determining the nodal status.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2000 May;85(7):817-23 [10792159.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Eur J Biochem. 2000 Aug;267(15):4720-30 [10903505.001]
  • [Cites] Free Radic Biol Med. 2000 May 1;28(9):1379-86 [10924857.001]
  • [Cites] Nature. 2000 Sep 7;407(6800):102-6 [10993082.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6877-84 [11359848.001]
  • [Cites] Am J Hum Genet. 2001 Jul;69(1):138-47 [11404819.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14):4604-13 [11416138.001]
  • [Cites] Mutat Res. 2001 Sep 1;480-481:349-58 [11506827.001]
  • [Cites] Mol Diagn. 2001 Dec;6(4):217-25 [11774186.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 26;293(1):509-16 [12054630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8054-9 [12060752.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2766-74 [12231515.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6966-72 [12460914.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Urol Int. 2003;70(3):167-71 [12660451.001]
  • [Cites] Thromb Haemost. 2003 Jun;89(6):1089-97 [12783123.001]
  • [Cites] Histopathology. 2003 Sep;43(3):272-9 [12940780.001]
  • [Cites] Cancer Sci. 2003 Sep;94(9):751-6 [12967471.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5454-61 [14500381.001]
  • [Cites] Curr Mol Med. 2003 Nov;3(7):631-42 [14601637.001]
  • [Cites] Nature. 1999 Apr 29;398(6730):824-8 [10235266.001]
  • [Cites] Urology. 1999 Sep;54(3):567-72 [10475375.001]
  • [Cites] Radiology. 2004 Nov;233(2):449-56 [15375228.001]
  • [Cites] Exp Cell Res. 2005 Feb 15;303(2):321-30 [15652346.001]
  • [Cites] Circulation. 2005 Jan 25;111(3):349-55 [15642762.001]
  • [Cites] Cell Res. 2005 Jan;15(1):11-8 [15686620.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):14675-83 [15677464.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):943-50 [15774488.001]
  • [Cites] Rays. 2004 Oct-Dec;29(4):373-6 [15852722.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3773-7 [15897575.001]
  • [Cites] BJU Int. 2005 Jul;96(1):7-12 [15963111.001]
  • [Cites] Genomics. 1994 Apr;20(3):463-7 [8034319.001]
  • [Cites] Nature. 1995 Mar 9;374(6518):193-6 [7877695.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8871-5 [7568034.001]
  • [Cites] Stat Med. 1997 Oct 15;16(19):2143-56 [9330425.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jul;19(1):6-17 [9651175.001]
  • [Cites] Mol Cell. 1998 Aug;2(2):213-22 [9734358.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6533-9 [16116151.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2005 Dec;27(12):1988-95 [16355665.001]
  • [Cites] Nat Clin Pract Urol. 2004 Nov;1(1):4-5 [16474441.001]
  • [Cites] BMC Bioinformatics. 2006;7:16 [16409628.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):499-506 [14745865.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):320-44 [15187187.001]
  • [Cites] Mol Cancer. 2004 Jan 23;3:5 [14741054.001]
  • [Cites] Traffic. 2004 Aug;5(8):571-6 [15260827.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1166-70 [15336964.001]
  • [Cites] Mol Cell. 2000 Apr;5(4):753-60 [10882111.001]
  • (PMID = 16780590.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA065726; United States / NCI NIH HHS / CA / CA-86871; United States / NCI NIH HHS / CA / CA-65726; United States / NCI NIH HHS / CA / P01 CA086871; United States / NCI NIH HHS / CA / CA-70903
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1550424
  •  go-up   go-down


19. Helpap B, Egevad L: Correlation of modified Gleason grading with pT stage of prostatic carcinoma after radical prostatectomy. Anal Quant Cytol Histol; 2008 Feb;30(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 29% of the tumors were upgraded.
  • Stage pT2 tumors were assigned a GS of 3-6 less often with modified grading than with conventional grading (29% and 84%, respectively).
  • Of GS 3 + 4 = 7a tumors, 95% were stage pT2, while 79% of GS 4 + 3 = 7b tumors were stage pT3-4.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459581.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fernandes N, Bailey DE, Vanvranken DL, Allbritton NL: Use of docking peptides to design modular substrates with high efficiency for mitogen-activated protein kinase extracellular signal-regulated kinase. ACS Chem Biol; 2007 Oct 19;2(10):665-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the ERK cascade occur in 30% of malignant tumors.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1991 Apr;10(4):885-92 [1849075.001]
  • [Cites] Mol Cell. 2002 Jun;9(6):1241-9 [12086621.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5341-5 [1608942.001]
  • [Cites] Cell Growth Differ. 1992 Feb;3(2):135-42 [1504018.001]
  • [Cites] J Biol Chem. 1993 Jul 15;268(20):14553-6 [8325833.001]
  • [Cites] Nature. 1994 Feb 24;367(6465):704-11 [8107865.001]
  • [Cites] Curr Opin Genet Dev. 1994 Feb;4(1):82-9 [8193545.001]
  • [Cites] Genes Dev. 1994 Dec 15;8(24):2996-3007 [8001819.001]
  • [Cites] Semin Cancer Biol. 1994 Aug;5(4):261-8 [7803762.001]
  • [Cites] J Biol Chem. 1995 Jul 14;270(28):16483-6 [7622446.001]
  • [Cites] Biochemistry. 1996 May 7;35(18):5641-6 [8639522.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6486-93 [8887677.001]
  • [Cites] J Mol Med (Berl). 1996 Oct;74(10):589-607 [8912180.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11057-62 [9110999.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2231-42 [12369850.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):1077-85 [12529172.001]
  • [Cites] Cell Signal. 2003 May;15(5):455-62 [12639708.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):554-65 [12815381.001]
  • [Cites] Mol Cell. 2004 Apr 9;14(1):43-55 [15068802.001]
  • [Cites] Mol Cell Biol. 1998 Feb;18(2):710-20 [9447967.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] J Biol Chem. 1999 Jan 29;274(5):2893-8 [9915826.001]
  • [Cites] Genes Dev. 1999 Jan 15;13(2):163-75 [9925641.001]
  • [Cites] Prog Biophys Mol Biol. 1999;71(3-4):479-500 [10354710.001]
  • [Cites] J Am Chem Soc. 2005 Aug 3;127(30):10494-5 [16045329.001]
  • [Cites] Biochim Biophys Acta. 2005 Dec 30;1754(1-2):253-62 [16198162.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5326-31 [16567630.001]
  • [Cites] Science. 2006 Apr 14;312(5771):217-24 [16614209.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):824-8 [16627995.001]
  • [Cites] Structure. 2006 Jun;14(6):1011-9 [16765894.001]
  • [Cites] J Am Chem Soc. 2007 Mar 14;129(10):2742-3 [17305340.001]
  • [Cites] Anal Chem. 2007 Mar 15;79(6):2570-5 [17261026.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jul;8(7):530-41 [17585314.001]
  • [Cites] J Biol Chem. 1999 Nov 26;274(48):34029-35 [10567369.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):110-6 [10655591.001]
  • [Cites] Biochemistry. 2000 Feb 29;39(8):2079-87 [10684658.001]
  • [Cites] Nat Biotechnol. 2000 Mar;18(3):309-12 [10700147.001]
  • [Cites] EMBO J. 2000 Mar 15;19(6):1301-11 [10716930.001]
  • [Cites] Trends Biochem Sci. 2000 Sep;25(9):448-53 [10973059.001]
  • [Cites] Nat Cell Biol. 1999 Nov;1(7):438-43 [10559988.001]
  • [Cites] EMBO J. 2001 Feb 1;20(3):466-79 [11157753.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10374-86 [11134045.001]
  • [Cites] Trends Cell Biol. 2001 Dec;11(12):504-11 [11719057.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):127-37 [11782450.001]
  • [Cites] J Neurosci Methods. 2002 Apr 30;116(1):29-34 [12007981.001]
  • [Cites] J Biol Chem. 1991 Aug 15;266(23):15180-4 [1907971.001]
  • (PMID = 17918909.001).
  • [ISSN] 1554-8937
  • [Journal-full-title] ACS chemical biology
  • [ISO-abbreviation] ACS Chem. Biol.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB004436-05; United States / NIBIB NIH HHS / EB / R01 EB004436; United States / NIBIB NIH HHS / EB / R01 EB004436-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS62781; NLM/ PMC2597387
  •  go-up   go-down


22. Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H: Role of Stat3 in regulating p53 expression and function. Mol Cell Biol; 2005 Sep;25(17):7432-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, most natural p53 mutations occur at a late stage in tumor development, and many clinically detectable cancers have reduced p53 expression but no p53 mutations.
  • It remains to be fully determined what mechanisms disable p53 during malignant initiation and in cancers without mutations that directly affect p53.
  • Furthermore, blocking Stat3 in cancer cells up-regulates expression of p53, leading to p53-mediated tumor cell apoptosis.
  • Thus, repression of p53 expression by Stat3 is likely to have an important role in development of tumors, and targeting Stat3 represents a novel therapeutic approach for p53 reactivation in many cancers lacking p53 mutations.
  • [MeSH-major] DNA-Binding Proteins / metabolism. Gene Expression Regulation. Trans-Activators / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Animals. Apoptosis. Cell Proliferation / radiation effects. Electrophoretic Mobility Shift Assay. Humans. Mice. Neoplasms / genetics. Neoplasms / metabolism. Neoplasms / pathology. Promoter Regions, Genetic / genetics. Response Elements / genetics. STAT3 Transcription Factor. Signal Transduction. Transcription, Genetic / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1998 May;18(5):2545-52 [9566874.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):195-200 [9419352.001]
  • [Cites] Annu Rev Biochem. 1998;67:227-64 [9759489.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] J Pathol. 1999 Jan;187(1):112-26 [10341712.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12):1968-73 [10471047.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):740-9 [12360277.001]
  • [Cites] Nat Med. 2004 Jan;10(1):48-54 [14702634.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):97-105 [14964307.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3550-60 [15116091.001]
  • [Cites] Cell. 1981 Mar;23(3):731-9 [7226226.001]
  • [Cites] Mol Cell Biol. 1985 May;5(5):1073-83 [2582237.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7717-22 [2253215.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] EMBO J. 1990 Dec;9(13):4477-84 [2176154.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Anal Biochem. 1992 Jan;200(1):81-8 [1595905.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):83-6 [1614538.001]
  • [Cites] Genes Dev. 1992 Oct;6(10):1886-98 [1398068.001]
  • [Cites] Mol Cell Biol. 1992 Dec;12(12):5581-92 [1448088.001]
  • [Cites] Mol Cell Biol. 1993 Jul;13(7):4107-14 [7686617.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2468-73 [10851045.001]
  • [Cites] Oncogene. 2000 Jun 1;19(24):2867-9 [10851090.001]
  • [Cites] Nature. 2000 Jun 22;405(6789):974-8 [10879542.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Immunity. 2001 Feb;14(2):193-204 [11239451.001]
  • [Cites] Semin Cancer Biol. 2001 Feb;11(1):23-30 [11243896.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3276-80 [11309279.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):517-28 [11463377.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45443-55 [11579100.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):217-26 [11803465.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):376-80 [11809683.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):514-24 [11847100.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):331-41 [12044009.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3082-8 [12082540.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62 [12209125.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3041-5 [7708771.001]
  • [Cites] Science. 1995 Jul 7;269(5220):81-3 [7541555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):940-4 [8570664.001]
  • [Cites] J Biol Chem. 1996 Jul 12;271(28):16798-806 [8663329.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3651-8 [8670868.001]
  • [Cites] Science. 1996 Aug 9;273(5276):794-7 [8670419.001]
  • [Cites] Oncogene. 1996 Dec 5;13(11):2359-66 [8957077.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Mol Med. 1997 Apr;3(4):248-59 [9131587.001]
  • [Cites] Cell. 1997 Nov 28;91(5):649-59 [9393858.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2553-8 [9566875.001]
  • (PMID = 16107692.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Stat3 protein, mouse; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1190305
  •  go-up   go-down


23. Spano JP, Carcelain G, Katlama C, Costagliola D: [Non-AIDS-defining malignancies in HIV patients: clinical features and perspectives]. Bull Cancer; 2006 Jan;93(1):37-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Les nouvelles tumeurs malignes du patient infecté par le VIH: aspects cliniques et perspectives.
  • Indeed, malignant tumors currently rank among the leading cause of morbidity and mortality in patients infected with HIV.
  • In addition to the AIDS-malignancies, non-AIDS defining tumors have a higher incidence than the general population such as Hodgkin disease, lung cancer, cutaneaous cancer and anal cancer.
  • These malignant tumors are generally characterized by a more aggressive behaviour at diagnosis and a poorer outcome compared with the same tumors in the general population.
  • These recommendations might be the fruit of a new networking between HIV specialists and oncologists and of an improving knowledge of the pathogenesis and clinical features of these AIDS non-defining tumors.
  • [MeSH-major] HIV Infections / complications. HIV Infections / diagnosis. Neoplasms / physiopathology. Neoplasms / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455504.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 48
  •  go-up   go-down


24. Gonzalez RF, Allen L, Gonzales L, Ballard PL, Dobbs LG: HTII-280, a biomarker specific to the apical plasma membrane of human lung alveolar type II cells. J Histochem Cytochem; 2010 Oct;58(10):891-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HTII-280 is likely to be a useful morphological and biochemical marker of human TII cells that may help to advance our understanding of various lung pathological conditions, including the origin and development of various lung tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Respir J. 1999 Sep;14(3):534-44 [10543272.001]
  • [Cites] Cytometry A. 2010 Jan;77(1):6-10 [20024907.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):990-5 [10712353.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jun;280(6):L1318-26 [11350813.001]
  • [Cites] Eur J Immunol. 2003 Sep;33(9):2619-29 [12938238.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Feb;286(2):L382-7 [14578117.001]
  • [Cites] Expert Rev Mol Med. 2003 Oct;5(26):1-12 [14987401.001]
  • [Cites] Exp Mol Pathol. 1975 Feb;22(1):142-50 [163758.001]
  • [Cites] Anal Biochem. 1984 Nov 1;142(2):336-9 [6528972.001]
  • [Cites] Biochim Biophys Acta. 1985 Jul 30;846(1):155-66 [3839418.001]
  • [Cites] Am Rev Respir Dis. 1986 Jul;134(1):141-5 [3637065.001]
  • [Cites] J Histochem Cytochem. 1986 Sep;34(9):1137-48 [2426341.001]
  • [Cites] Biochim Biophys Acta. 1988 Jun 30;970(2):146-56 [3382696.001]
  • [Cites] Histochem J. 1989 Mar;21(3):163-71 [2722561.001]
  • [Cites] Cell Growth Differ. 1990 Nov;1(11):511-8 [2088477.001]
  • [Cites] Annu Rev Physiol. 1991;53:395-414 [2042966.001]
  • [Cites] Am J Respir Cell Mol Biol. 1992 Jun;6(6):594-600 [1591008.001]
  • [Cites] J Comp Neurol. 1992 Nov 1;325(1):38-46 [1484117.001]
  • [Cites] Am Rev Respir Dis. 1992 Aug;146(2):454-6 [1489139.001]
  • [Cites] Dev Biol. 1995 Jan;167(1):294-306 [7851650.001]
  • [Cites] Am J Physiol. 1995 Feb;268(2 Pt 1):L181-6 [7864138.001]
  • [Cites] Histochem Cell Biol. 1995 Apr;103(4):281-6 [7648403.001]
  • [Cites] Bone. 1996 Feb;18(2):125-32 [8833206.001]
  • [Cites] Am J Physiol. 1997 Apr;272(4 Pt 1):L631-8 [9142935.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2991-6 [9501203.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Eur Respir J. 1998 Dec;12(6):1397-403 [9877498.001]
  • [Cites] J Histochem Cytochem. 1999 Feb;47(2):129-37 [9889249.001]
  • [Cites] Dev Dyn. 1999 Aug;215(4):319-31 [10417821.001]
  • [Cites] Chest. 1999 Jul;116(1 Suppl):35S-36S [10424584.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Jan;288(1):L179-89 [15447939.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):58-68 [15630429.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Sep;289(3):L382-90 [15849211.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):4964-9 [16549766.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Aug;293(2):L259-71 [17496061.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Dec 15;176(12):1261-8 [17641155.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2008 Sep;295(3):L379-99 [18621912.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2009 Dec;297(6):L1045-55 [19717550.001]
  • [Cites] Am J Cardiol. 1999 Dec 15;84(12):1440-2, A6, A8 [10606119.001]
  • (PMID = 20566753.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL-57426; United States / NHLBI NIH HHS / HL / R01 HL057426; United States / NHLBI NIH HHS / HL / HL-099820; United States / NHLBI NIH HHS / HL / R01 HL088193; United States / NHLBI NIH HHS / HL / RC1 HL099820; United States / NHLBI NIH HHS / HL / P01 HL024075; United States / NHLBI NIH HHS / HL / HL-24075; United States / NHLBI NIH HHS / HL / HL-086323; United States / NHLBI NIH HHS / HL / R01 HL086323
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2942742
  •  go-up   go-down


25. Elstner A, Holtkamp N, von Deimling A: Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. Clin Exp Metastasis; 2007;24(1):57-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme are highly invasive brain tumors.
  • Experimental approaches focus on unravelling the mechanisms of invasion, this being a major reason for the poor prognosis of these tumors.
  • These findings caution on utilization of DFO and other iron chelators in the treatment of tumors with invasive potential.
  • [MeSH-major] Brain Neoplasms / metabolism. Deferoxamine / pharmacology. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Iron Chelating Agents / pharmacology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cell Separation. Flow Cytometry. Humans. Iron / metabolism. Matrix Metalloproteinase 2 / drug effects. Matrix Metalloproteinase 2 / metabolism. RNA, Small Interfering. Receptors, Cell Surface / drug effects. Receptors, Cell Surface / metabolism. Receptors, Urokinase Plasminogen Activator. Transfection

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DESFERRIOXAMINE .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1399-408 [16170032.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 4;336(4):1227-33 [16171788.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3747-51 [8706019.001]
  • [Cites] Anticancer Res. 1995 Sep-Oct;15(5B):2347-50 [8572650.001]
  • [Cites] Oncogene. 2000 Aug 31;19(37):4210-20 [10980594.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6624-8 [11559524.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):709-13 [10543996.001]
  • [Cites] J Neurosurg. 1990 Jun;72(6):941-5 [2159987.001]
  • [Cites] Oncogene. 2004 Nov 4;23(52):8486-96 [15378018.001]
  • [Cites] Blood. 2006 May 1;107(9):3455-62 [16352812.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):617-23 [9935166.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):7189-92 [3191493.001]
  • [Cites] Cancer Lett. 2006 Jul 18;238(2):188-96 [16111806.001]
  • [Cites] J Neurooncol. 2004 May;67(3):367-77 [15164994.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):93-101 [9120549.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1450-8 [15150082.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):39-45 [14756439.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):369-74 [16391791.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1138-43 [12615733.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3610-5 [8260699.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Curr Top Med Chem. 2004;4(15):1623-35 [15579100.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2714-24 [12171905.001]
  • [Cites] J Cell Sci. 2002 May 15;115(Pt 10):2165-77 [11973357.001]
  • [Cites] J Neurooncol. 2000;46(2):115-23 [10894364.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6845-8 [15466170.001]
  • [Cites] J Lab Clin Med. 1998 Apr;131(4):306-15 [9579383.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):161-76 [11716068.001]
  • [Cites] Oral Oncol. 2005 Nov;41(10):971-7 [16129656.001]
  • [Cites] Baillieres Clin Haematol. 1989 Apr;2(2):345-62 [2660932.001]
  • [Cites] Blood. 1987 Mar;69(3):757-61 [3493042.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):73-81 [16773187.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2379-92 [16369494.001]
  • [Cites] Biochem Pharmacol. 1996 Jun 14;51(11):1553-61 [8630097.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1624-36 [12697889.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5040-51 [15923621.001]
  • [Cites] Anal Biochem. 2004 Aug 15;331(2):370-5 [15265744.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):883-7 [10706099.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1876-82 [14604972.001]
  • [Cites] J Cell Physiol. 2003 Aug;196 (2):394-402 [12811834.001]
  • [Cites] Biochem Cell Biol. 1990 Dec;68(12):1364-71 [2085432.001]
  • (PMID = 17357815.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Iron Chelating Agents; 0 / PLAUR protein, human; 0 / RNA, Small Interfering; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; E1UOL152H7 / Iron; EC 3.4.24.24 / Matrix Metalloproteinase 2; J06Y7MXW4D / Deferoxamine
  •  go-up   go-down


26. Irons R, Tsuji PA, Carlson BA, Ouyang P, Yoo MH, Xu XM, Hatfield DL, Gladyshev VN, Davis CD: Deficiency in the 15-kDa selenoprotein inhibits tumorigenicity and metastasis of colon cancer cells. Cancer Prev Res (Phila); 2010 May;3(5):630-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas most (14 of 15) BALB/c mice injected with control cells developed tumors, few (3 of 30) mice injected with Sep15-deficient cells developed tumors (P < 0.0001).
  • Mice injected with the plasmid-transfected control cells had >250 lung metastases per mouse; however, mice injected with cells with downregulation of Sep15 only had 7.8 +/- 5.4 metastases.

  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Oncogene. 2009 Aug 20;28(33):2959-68 [19543318.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35540-7 [10945981.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2109-22 [12612082.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Science. 2003 May 30;300(5624):1439-43 [12775843.001]
  • [Cites] J Nutr. 2003 Sep;133(9):2721-7 [12949356.001]
  • [Cites] J Nutr. 2003 Sep;133(9):2907-14 [12949386.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):5032-40 [15107826.001]
  • [Cites] J Lab Clin Med. 1967 Jul;70(1):158-69 [6066618.001]
  • [Cites] Methods Enzymol. 1995;252:199-208 [7476354.001]
  • [Cites] Dis Colon Rectum. 1996 Jun;39(6):628-31 [8646947.001]
  • [Cites] JAMA. 1996 Dec 25;276(24):1957-63 [8971064.001]
  • [Cites] Anal Biochem. 1997 Nov 1;253(1):123-5 [9356150.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5542-8 [15611090.001]
  • [Cites] J Biol Chem. 2005 Dec 16;280(50):41568-75 [16230358.001]
  • [Cites] J Nutr. 2006 May;136(5):1311-7 [16614422.001]
  • [Cites] J Biol Chem. 2006 May 12;281(19):13005-8 [16565519.001]
  • [Cites] IUBMB Life. 2007 Jan;59(1):1-5 [17365173.001]
  • [Cites] Oncogene. 2007 Jul 19;26(33):4825-32 [17297447.001]
  • [Cites] PLoS One. 2007;2(10):e1112 [17971875.001]
  • [Cites] Eur J Nutr. 2008 Feb;47(1):47-54 [18239845.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(20):6102-9 [11012661.001]
  • (PMID = 20388823.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA080946; United States / Intramural NIH HHS / / Z99 CA999999; United States / NCI NIH HHS / CA / CA080946
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Selenoproteins; 0 / Sep15 protein, mouse
  • [Other-IDs] NLM/ NIHMS184300; NLM/ PMC2865577
  •  go-up   go-down


27. Liu Y, Yan S, Wondimu A, Bob D, Weiss M, Sliwinski K, Villar J, Notario V, Sutherland M, Colberg-Poley AM, Ladisch S: Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth. Oncogene; 2010 Jun 3;29(22):3297-306
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth.
  • Biologically active membrane gangliosides, expressed and released by many human tumors, are hypothesized to significantly impact tumor progression.
  • Lack of a model of complete and specific tumor ganglioside depletion in vivo, however, has hampered elucidation of their role.
  • Here, we report the creation of a novel, stable, genetically induced tumor cell system resulting in specific and complete blockade of ganglioside synthesis.
  • Strikingly, despite similar oncogene expression and growth kinetics, DKO(t) cells evidenced significantly impaired tumor growth in syngeneic immunocompetent mice, underscoring the pivotal role of tumor cell gangliosides and providing an ideal system for probing their mechanisms of action in vivo.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42782-92 [11535585.001]
  • [Cites] Biol Chem. 2009 Jul;390(7):601-9 [19335207.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):471-80 [12163372.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Oct;28(5):343-57 [12366816.001]
  • [Cites] Curr Opin Struct Biol. 2002 Oct;12(5):587-92 [12464309.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3445-9 [12629211.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36481-9 [15215248.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1225-9 [15502825.001]
  • [Cites] Adv Cancer Res. 1973;18:265-315 [4587356.001]
  • [Cites] J Supramol Struct. 1978;8(1):1-17 [366282.001]
  • [Cites] Cancer Res. 1983 Aug;43(8):3808-13 [6861145.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):363-9 [11196188.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):6021-30 [11698483.001]
  • [Cites] Anal Biochem. 1985 Apr;146(1):220-31 [3993932.001]
  • [Cites] J Clin Invest. 1987 Jun;79(6):1879-82 [3584474.001]
  • [Cites] Int J Cancer. 1989 Jan 15;43(1):6-9 [2910832.001]
  • [Cites] Cell. 1989 Mar 24;56(6):917-30 [2538247.001]
  • [Cites] J Cell Physiol. 1989 Dec;141(3):573-83 [2531751.001]
  • [Cites] Blood. 1990 Apr 1;75(7):1564-7 [2317562.001]
  • [Cites] Biochim Biophys Acta. 1991 Apr 24;1083(1):57-64 [2031938.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2859-67 [7852361.001]
  • [Cites] J Biol Chem. 1996 Aug 9;271(32):19530-6 [8702646.001]
  • [Cites] Cytometry. 1996 Jun 1;24(2):131-9 [8725662.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] J Clin Invest. 1999 Sep;104(6):769-76 [10491412.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):685-91 [10521808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2725-30 [15710896.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35545-53 [16103120.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9824-8 [16267004.001]
  • [Cites] Indian J Exp Biol. 2005 Dec;43(12):1130-8 [16359123.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10408-14 [17079461.001]
  • [Cites] Arch Biochem Biophys. 2007 Jun 15;462(2):171-5 [17467652.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1771(9):1226-34 [17604219.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10859-68 [18006831.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):421-33 [17991443.001]
  • [Cites] Glycobiology. 2008 Aug;18(8):593-601 [18480157.001]
  • [Cites] Glycobiology. 2002 Mar;12(3):145-52 [11971858.001]
  • (PMID = 20305696.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA061010; United States / NCI NIH HHS / CA / CA64472; United States / NCI NIH HHS / CA / CA42361; United States / NCI NIH HHS / CA / R01 CA042361; None / None / / R01 CA042361-17; United States / NCI NIH HHS / CA / R01 CA064472; United States / NCI NIH HHS / CA / CA061010-14A1; United States / NIGMS NIH HHS / GM / GM62116; United States / NCI NIH HHS / CA / R01 CA061010-14A1; United States / NIGMS NIH HHS / GM / U54 GM062116; United States / NCI NIH HHS / CA / R01 CA042361-17; United States / NCI NIH HHS / CA / CA61010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gangliosides; EC 2.4.1.- / N-Acetylgalactosaminyltransferases; EC 2.4.1.92 / (N-acetylneuraminyl)-galactosylglucosylceramide N-acetylgalactosaminyltransferase; EC 2.4.99.- / Sialyltransferases; EC 2.4.99.9 / haematoside synthetase
  • [Other-IDs] NLM/ NIHMS179291; NLM/ PMC2880627
  •  go-up   go-down


28. Dakir EL H, Feigenbaum L, Linnoila RI: Constitutive expression of human keratin 14 gene in mouse lung induces premalignant lesions and squamous differentiation. Carcinogenesis; 2008 Dec;29(12):2377-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aging CC10-hK14 mice revealed multifocal airway cell hyperplasia, occasional squamous metaplasia and their lung tumors displayed evidence for multidirectional differentiation.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 1990 Dec;2(6):1028-35 [1712211.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):120-8 [1967140.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1992;61(6):375-87 [1349777.001]
  • [Cites] J Natl Cancer Inst Monogr. 1992;(13):93-100 [1327037.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Nov 30;197(1):163-71 [7916613.001]
  • [Cites] J Biol Chem. 1995 Feb 10;270(6):2689-94 [7852338.001]
  • [Cites] Cell Growth Differ. 1997 Feb;8(2):145-55 [9040936.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):487-99 [9786957.001]
  • [Cites] Gene. 1998 Dec 11;224(1-2):59-66 [9931436.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L625-32 [15579627.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):328-40 [15803139.001]
  • [Cites] Am J Respir Cell Mol Biol. 2005 Nov;33(5):455-62 [16055670.001]
  • [Cites] Curr Mol Med. 2007 Feb;7(1):3-14 [17311529.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Aug;322(2):529-40 [17496163.001]
  • [Cites] Nature. 2007 Aug 16;448(7155):807-10 [17676035.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] J Invest Dermatol. 2008 Jun;128(6):1517-24 [18049449.001]
  • [Cites] J Cell Biol. 2000 Apr 3;149(1):17-22 [10747083.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4005-9 [10945598.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13031-6 [11698679.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Transgenic Res. 2002 Feb;11(1):21-9 [11874100.001]
  • [Cites] Respir Res. 2002;3:20 [11980589.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Pathol Int. 2002 Apr;52(4):286-93 [12031084.001]
  • [Cites] Bioessays. 2002 Sep;24(9):789-800 [12210515.001]
  • [Cites] Am J Pathol. 2004 Feb;164(2):577-88 [14742263.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1647-54 [14996723.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1207-13 [15140224.001]
  • [Cites] J Mol Biol. 1975 Nov 5;98(3):503-17 [1195397.001]
  • [Cites] Lab Invest. 1978 Jun;38(6):648-53 [661220.001]
  • [Cites] J Anat. 1981 Jan;132(Pt 1):71-84 [7275793.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;45(2):221-40 [6143448.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(7):1991-5 [6326095.001]
  • [Cites] Anal Biochem. 1984 Feb;137(1):266-7 [6329026.001]
  • [Cites] J Immunol. 1985 Oct;135(4):2589-92 [4031496.001]
  • [Cites] EMBO J. 1986 Jul;5(7):1567-75 [3017704.001]
  • [Cites] Cell. 1987 Feb 13;48(3):453-63 [2433047.001]
  • [Cites] Lab Invest. 1987 Aug;57(2):219-29 [3613528.001]
  • [Cites] J Invest Dermatol. 1989 Feb;92(2):203-9 [2465352.001]
  • [Cites] Mol Cell Biol. 1989 Sep;9(9):3685-97 [2476664.001]
  • [Cites] Am J Clin Pathol. 1992 Feb;97(2):233-43 [1372146.001]
  • (PMID = 18701433.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRT14 protein, human; 0 / Keratin-14
  • [Other-IDs] NLM/ PMC2639248
  •  go-up   go-down


29. Chekerov R, Klaman I, Zafrakas M, Könsgen D, Mustea A, Petschke B, Lichtenegger W, Sehouli J, Dahl E: Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. Neoplasia; 2006 Jan;8(1):38-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression pattern of topoisomerase IIalpha in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy.
  • METHODS: TOP2A expression was analyzed prospectively in normal and tumor epithelial and adjacent stromal cells using quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) after laser microdissection (n = 38), RNA in situ hybridization (n = 13), and immunohistochemistry (n = 69).
  • RESULTS: TOP2A mRNA was detected by RNA in situ hybridization in all ovarian cancer samples, with stronger hybridization signals in tumor epithelial cells compared to adjacent stromal cells.
  • Very interestingly, specific change was found in recurrent ovarian cancer after platinum-based chemotherapy: TOP2A expression decreased in tumor epithelial cells of recurrent ovarian cancer compared to primary ovarian cancer (P = .056), whereas it increased in tumor-adjacent stromal cells in carboplatin-treated recurrent tumors compared to primary ovarian cancer (P = .023).
  • CONCLUSION: TOP2A mRNA and protein expression in ovarian cancer exhibits specific patterns in tumor epithelial and adjacent stromal cells, which are differentially modulated after platinum-based chemotherapy.
  • These data support the recently discovered importance of the stromal compartment in tumor progression and suggest that tumor stromal cells might be relevant to the development of chemotherapy resistance in ovarian cancer.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Drug Resistance, Neoplasm. Epithelial Cells / metabolism. Female. Humans. Lasers. Microdissection. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):257-74 [9748618.001]
  • [Cites] J Med Invest. 2005 Feb;52(1-2):41-8 [15751272.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):348-56 [15891995.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):921-7 [10970695.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):666-72 [11041055.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):54-9 [11163151.001]
  • [Cites] Pathobiology. 2000;68(4-5):209-14 [11279348.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):107-38 [11385772.001]
  • [Cites] Breast Cancer Res. 2001;3(4):224-9 [11434873.001]
  • [Cites] Int J Gynecol Cancer. 2001;11 Suppl 1:7-11 [11488996.001]
  • [Cites] Int J Gynecol Cancer. 2001;11 Suppl 1:52-6 [11489004.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):2925-32 [11712788.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):691-7 [11895897.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Zentralbl Gynakol. 2002 Mar;124(3):176-83 [12070798.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Nov;34(11):1401-14 [12200035.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1673-9 [12738720.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):764-72 [14566826.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1403-10 [14973057.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):887-95 [14984957.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):548-53 [14991576.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):19-31 [15034864.001]
  • [Cites] Obstet Gynecol. 1982 May;59(5):576-82 [7070728.001]
  • [Cites] J Cell Biol. 1986 Dec;103(6 Pt 2):2569-81 [3025219.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] NCI Monogr. 1987;(4):61-71 [2819733.001]
  • [Cites] Adv Cancer Res. 1988;50:159-96 [3287842.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431-5 [2556712.001]
  • [Cites] Cancer Res. 1991 Nov 1;51(21):5915-20 [1682037.001]
  • [Cites] Int J Cancer. 1996 Aug 7;67(4):479-84 [8759604.001]
  • [Cites] Nucleic Acids Res. 1996 Nov 15;24(22):4464-70 [8948636.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):275-88 [9748627.001]
  • [Cites] Gene. 1998 Oct 23;221(2):255-66 [9795238.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1329-33 [9809560.001]
  • [Cites] J Obstet Gynaecol Res. 1998 Dec;24(6):447-51 [10063241.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 1:43-50 [10219452.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3206-14 [10397267.001]
  • [Cites] J Histochem Cytochem. 1997 Feb;45(2):251-63 [9016314.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5 [9448283.001]
  • [Cites] Mol Pathol. 1997 Oct;50(5):247-53 [9497914.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):139-54 [9748545.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • (PMID = 16533424.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC1584288
  •  go-up   go-down


30. Versa-Ostojić D, Stanković T, Stemberger-Papić S, Vrdoljak-Mozetic D, Manestar M, Krasević M: Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints. Anal Quant Cytol Histol; 2008 Jun;30(3):160-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints.
  • OBJECTIVE: To determine the morphometric characteristics of nuclei and silver-stained nucleolar organizer regions (AgNORs) on cytologic imprints and their value in differential cytodiagnosis of benign, atypical proliferative (borderline) and malignant ovarian mucinous tumors.
  • STUDY DESIGN: Forty-six mucinous ovarian tumor imprints (16 benign, 15 borderline, 15 malignant), were analyzed.
  • AgNOR quantification included 7 variables related to the number and area of single, cluster, total and relative AgNOR content per nucleus and the size distribution of AgNORs.
  • RESULTS: Nuclear area and shape factor allowed distinguishing borderline and malignant tumors.
  • The nuclear area in benign tumors was larger than that in borderline tumors; malignant tumors had the highest values.
  • Single and cluster AgNORs were statistically significantly different in borderline tumors compared with malignant tumors, except for the cluster AgNOR area.
  • The total AgNOR area, number and relative area increased from benign through malignant tumors, with statistically significant differences among all groups.
  • By AgNOR size distribution, small AgNORs discriminate malignant from borderline and benign tumors.
  • CONCLUSION: Combining nuclear morphometry and AgNOR analysis on cytologic imprints could be a diagnostically useful method in the assessment of mucinous ovarian tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630841.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down


31. Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, Saltz LB, Qin J, Landmann R, Leonard GD, Dhall D, Temple L, Guillem JG, Paty PB, Kelsen D, Wong WD, Klimstra DS: Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol; 2008 May;32(5):719-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
  • Guided primarily by the World Health Organization/International Association for the Study of Lung Cancer criteria for pulmonary neuroendocrine tumors, we were able to classify 87 high-grade GI tract tumors that initially carried a diagnosis of either poorly differentiated carcinoma with or without any neuroendocrine characteristics, small cell carcinoma, or combined adenocarcinoma-neuroendocrine carcinoma into the following 4 categories.
  • In addition, 5 of the 87 tumors showed either nonsmall cell type neuroendocrine morphology (n=3) or immunohistochemical reactivity for neuroendocrine markers (n=2), but not both.
  • Further analysis showed that most HGNECs arising in the squamous lined parts (esophagus and anal canal) were small cell type (78%), whereas most involving the glandular mucosa were large cell (53%) or mixed (82%) type; associated adenocarcinomas were more frequent in large cell (61%) or mixed (36%) type than in small cell type (26%); and focal intracytoplasmic mucin was seen only in large cell or mixed type.
  • As a group, the 2-year disease-specific survival for patients with HGNEC was 25.4% (median follow-up time, 11.3 mo).
  • These tumors are clinically aggressive.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Small Cell / diagnosis. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Tract / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasms, Multiple Primary. New York / epidemiology. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360283.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


32. Molina R, Augé JM, Escudero JM, Filella X, Zanon G, Pahisa J, Farrus B, Muñoz M, Velasco M: Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol; 2010 Jun;31(3):171-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.
  • Tumor markers were studied in the sera of 883 untreated patients with primary breast cancer diagnosed between 1989 and 2007.
  • One or more tumor markers were abnormal in 305 (34.5%) of the 883 studied patients.
  • CEA, CA 15.3, and HER-2/neu (only in those patients with tissue overexpression) serum levels were related with tumor stage (tumor size and nodal involvement) and steroid receptors (higher values in estrogen receptor-negative (ER-) tumors).
  • Univariate analysis showed that HER-2/neu serum levels were prognostic factors in disease-free survival (DFS) and overall survival (OS) only in patients with tissue overexpression.
  • Multivariate analysis in 834 patients show that nodal involvement, tumor size, ER, CEA, and adjuvant treatment were independent prognostic factors in DFS and OS.
  • When only patients with HER-2/neu overexpression in tissue were studied, tumor size, nodal involvement, and tumor markers (one or another positive) were independent prognostic factors for both DFS and OS.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Carcinoembryonic Antigen / blood. Mucin-1 / blood. Receptor, ErbB-2 / blood
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Middle Aged


33. Gaspar JR, Qu J, Straubinger NL, Straubinger RM: Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometry. Analyst; 2008 Dec;133(12):1742-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometry.
  • Paclitaxel is used as first-line therapy for a variety of cancers, and numerous drug delivery approaches are under investigation to enhance its selectivity and effectiveness against tumors.
  • One strategy is to produce sustained, low drug levels within the tumor to enhance apoptosis and inhibit angiogenesis.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2007 May 15;79(10):3786-93 [17411010.001]
  • [Cites] J Med Chem. 2007 Feb 22;50(4):713-25 [17263521.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(14):2170-4 [16779869.001]
  • [Cites] Int Heart J. 2006 Jan;47(1):1-12 [16479035.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7794-803 [16172456.001]
  • [Cites] Drug Metab Dispos. 2005 Aug;33(8):1124-30 [15860658.001]
  • [Cites] Anticancer Drugs. 2005 Aug;16(7):691-707 [16027517.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2433-40 [15781659.001]
  • [Cites] Anal Biochem. 2005 Jan 15;336(2):213-20 [15620886.001]
  • [Cites] Int J Cancer. 1999 Oct 8;83(2):151-6 [10471519.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1454-7 [10197613.001]
  • [Cites] J Pharm Sci. 1995 Dec;84(12):1400-4 [8748320.001]
  • [Cites] J Pharm Sci. 1995 Oct;84(10):1223-30 [8801338.001]
  • [Cites] Pharm Res. 1994 Jun;11(6):889-96 [7937531.001]
  • [Cites] J Natl Cancer Inst Monogr. 1993;(15):69-78 [7912532.001]
  • [Cites] J Am Chem Soc. 1971 May 5;93(9):2325-7 [5553076.001]
  • [Cites] J Pharm Biomed Anal. 2004 Sep 21;36(1):125-31 [15351056.001]
  • [Cites] Endocrinology. 2004 Jul;145(7):3143-52 [15044368.001]
  • [Cites] AAPS PharmSci. 2003 Nov 21;5(4):E32 [15198520.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May 25;804(2):263-7 [15081919.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):821-4 [14871806.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):221-31 [14724301.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):159-66 [12759775.001]
  • [Cites] Rapid Commun Mass Spectrom. 2003;17(14):1548-52 [12845579.001]
  • [Cites] J Invest Dermatol. 2003 Mar;120(3):476-82 [12603862.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jan 5;783(1):231-6 [12450543.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1237-41 [11948138.001]
  • [Cites] Chem Rec. 2001;1(3):195-211 [11895119.001]
  • (PMID = 19082078.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / S10 RR021221; United States / NCI NIH HHS / CA / CA107570-01; United States / NCI NIH HHS / CA / CA107570-03S1; United States / NCI NIH HHS / CA / R01 CA107570-05; United States / NCRR NIH HHS / RR / S10RR14573; United States / NCRR NIH HHS / RR / S10 RR023650-01; United States / NCI NIH HHS / CA / CA107570-03; United States / NCRR NIH HHS / RR / S10 RR014592-01; United States / NCI NIH HHS / CA / R01 CA107570-01; United States / NCRR NIH HHS / RR / S10 RR023650; United States / NCRR NIH HHS / RR / RR023650-01; United States / NCI NIH HHS / CA / CA107570-02S1; United States / NCRR NIH HHS / RR / S10 RR021221-01; United States / NCI NIH HHS / CA / R01 CA107570; United States / NCI NIH HHS / CA / R01 CA107570-02S1; United States / NCRR NIH HHS / RR / RR021221-01; United States / NCI NIH HHS / CA / R01 CA107570-03S1; United States / NCRR NIH HHS / RR / RR014592-01; United States / NCI NIH HHS / CA / R01 CA107570-03; United States / NCI NIH HHS / CA / CA107570-05; United States / NCI NIH HHS / CA / R01CA107570
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS208140; NLM/ PMC2896315
  •  go-up   go-down


34. Sarzo G, Del Mistro A, Finco C, Frayle-Salamanca H, Marino F, Franzetti M, Ferrara R, Mistrangelo M, Savastano S, Vecchiato M, Merigliano S: Extensive anal condylomatosis: prognosis in relation to viral and host factors. Colorectal Dis; 2010 Jul;12(7 Online):e128-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive anal condylomatosis: prognosis in relation to viral and host factors.
  • OBJECTIVE: To evaluate the clinical course of extensive anal condylomatosis in relation to treatment modalities, patient comorbidity and immune function, and associated papillomavirus (HPV) sequences.
  • RESULTS: Sixteen patients [14 males, median age 41.8 years (range 19-66)] affected by extensive anal condylomatosis [10 Buschke-Lowenstein Tumors (BLT) and 6 condylomatosis] treated in three different Italian institutions were included.
  • There was associated preoperative anal intraepithelial neoplasia grade 3 (AIN3) in one and invasive carcinoma in three patients.
  • Typing of HPV sequences in the management of patients affected by extensive anal condylomatosis may be useful.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Colorectal Dis. 2010 Oct;12(10):1072. Mistro, A [corrected to Del Mistro, A]
  • (PMID = 19508521.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


35. Ding J, Jiang D, Kurczy M, Nalepka J, Dudley B, Merkel EI, Porter FD, Ewing AG, Winograd N, Burgess J, Molyneaux K: Inhibition of HMG CoA reductase reveals an unexpected role for cholesterol during PGC migration in the mouse. BMC Dev Biol; 2008 Dec 31;8:120
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Environmental or genetic defects that alter PGC development can impair fertility or cause formation of germ cell tumors.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1999;68:157-85 [10872447.001]
  • [Cites] Anal Chem. 2008 Feb 15;80(4):1235-9 [18197693.001]
  • [Cites] Trends Endocrinol Metab. 2000 Apr;11(3):106-14 [10707051.001]
  • [Cites] Hum Mol Genet. 2001 Mar 15;10(6):555-64 [11230174.001]
  • [Cites] Cell. 2001 Sep 21;106(6):759-69 [11572781.001]
  • [Cites] Development. 2002 May;129(10):2367-79 [11973269.001]
  • [Cites] J Clin Invest. 2002 Sep;110(5):591-6 [12208857.001]
  • [Cites] Mol Cell. 2003 Jan;11(1):25-33 [12535518.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5319-23 [12684531.001]
  • [Cites] Hum Mol Genet. 2003 Jul 1;12(13):1631-41 [12812989.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1715-25 [12829805.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):42936-41 [12920113.001]
  • [Cites] Dev Cell. 2004 Feb;6(2):283-93 [14960281.001]
  • [Cites] Dev Cell. 2004 Feb;6(2):295-302 [14960282.001]
  • [Cites] Gene Expr Patterns. 2004 Mar;4(2):167-81 [15161097.001]
  • [Cites] J Am Chem Soc. 2004 Aug 25;126(33):10214-5 [15315412.001]
  • [Cites] Acta Histochem. 1974;50(1):110-5 [4140671.001]
  • [Cites] Dev Biol. 1995 Nov;172(1):126-38 [7589793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10939-43 [7479914.001]
  • [Cites] Trends Genet. 1998 Mar;14(3):115-20 [9540409.001]
  • [Cites] Rapid Commun Mass Spectrom. 1998;12(18):1246-52 [9772767.001]
  • [Cites] Nature. 1998 Dec 3;396(6710):466-9 [9853754.001]
  • [Cites] Development. 1999 Apr;126(8):1655-64 [10079228.001]
  • [Cites] Mol Endocrinol. 1999 Sep;13(9):1460-73 [10478838.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30843-8 [10521476.001]
  • [Cites] Gene Expr Patterns. 2004 Nov;5(1):141-9 [15533830.001]
  • [Cites] Biol Reprod. 2005 Oct;73(4):639-47 [15917341.001]
  • [Cites] Dev Cell. 2005 Nov;9(5):629-38 [16256738.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] Cell Mol Life Sci. 2006 Feb;63(3):255-67 [16378247.001]
  • [Cites] Science. 2006 Sep 1;313(5791):1301-3 [16857902.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:237-65 [16774460.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2474-83 [17041091.001]
  • [Cites] Mech Dev. 2007 Jan;124(1):68-77 [17112707.001]
  • [Cites] Curr Biol. 2007 Feb 6;17(3):252-9 [17276918.001]
  • [Cites] Biol Cell. 2007 Mar;99(3):129-40 [17064251.001]
  • [Cites] Cell Motil Cytoskeleton. 2007 Mar;64(3):199-216 [17238130.001]
  • [Cites] Mol Membr Biol. 2007 Mar-Apr;24(2):91-101 [17453416.001]
  • [Cites] Anal Chem. 2007 May 15;79(10):3554-60 [17428032.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1739-47 [17554062.001]
  • [Cites] J Am Chem Soc. 2007 Sep 19;129(37):11352-3 [17718573.001]
  • [Cites] Development. 2008 Jan;135(1):111-21 [18045843.001]
  • [Cites] Biochem J. 2000 Sep 15;350 Pt 3:785-90 [10970793.001]
  • (PMID = 19117526.001).
  • [ISSN] 1471-213X
  • [Journal-full-title] BMC developmental biology
  • [ISO-abbreviation] BMC Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002016; United States / Intramural NIH HHS / / ; United States / NIBIB NIH HHS / EB / R01 EB002016-18; United States / NCRR NIH HHS / RR / RR-017980-01; United States / NCRR NIH HHS / RR / S10 RR017980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 97C5T2UQ7J / Cholesterol; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases
  • [Other-IDs] NLM/ PMC2631600
  •  go-up   go-down


36. Baumforth KR, Birgersdotter A, Reynolds GM, Wei W, Kapatai G, Flavell JR, Kalk E, Piper K, Lee S, Machado L, Hadley K, Sundblad A, Sjoberg J, Bjorkholm M, Porwit AA, Yap LF, Teo S, Grundy RG, Young LS, Ernberg I, Woodman CB, Murray PG: Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol; 2008 Jul;173(1):195-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In approximately 50% of patients with Hodgkin's lymphoma (HL), the Epstein-Barr virus (EBV), an oncogenic herpesvirus, is present in tumor cells.
  • After microarray profiling of both HL tumors and cell lines, we found that EBV infection increased the expression of the chemokine CCL20 in both primary Hodgkin and Reed-Sternberg cells and Hodgkin and Reed-Sternberg cell-derived cell lines.
  • Our results identify a mechanism by which EBV can recruit Tregs to the microenvironment of HL by inducing the expression of CCL20 and, by doing so, prevent immune responses against the virus-infected tumor population.
  • Further investigation of how EBV recruits and modifies Tregs will contribute not only to our understanding of the pathogenesis of virus-associated tumors but also to the development of therapeutic strategies designed to manipulate Treg activity.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2006 Oct 1;177(7):4488-94 [16982885.001]
  • [Cites] Springer Semin Immunopathol. 2006 Aug;28(1):51-62 [16841143.001]
  • [Cites] Acta Haematol. 2006;116(3):181-5 [17016036.001]
  • [Cites] J Virol. 2007 Jan;81(1):42-58 [17050609.001]
  • [Cites] Br J Haematol. 2007 Oct;139(1):81-9 [17854310.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] Anal Cell Pathol. 1996 Nov;12(2):71-83 [8986292.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):363-76 [10199466.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):650-7 [10225458.001]
  • [Cites] Cancer J. 2004 Nov-Dec;10(6):374-80 [15701269.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1898-904 [15542583.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2877-86 [15613550.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2138-46 [15933052.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1273-82 [16211222.001]
  • [Cites] Br J Haematol. 2006 Feb;132(3):293-302 [16409294.001]
  • [Cites] Scand J Immunol. 2006 Jun;63(6):468-77 [16764701.001]
  • [Cites] Int J Hematol. 2006 Jun;83(5):385-90 [16787867.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):363-71 [10830743.001]
  • [Cites] J Allergy Clin Immunol. 2000 Jul;106(1 Pt 2):S109-12 [10887343.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6219-26 [11507075.001]
  • [Cites] Mod Pathol. 2001 Dec;14(12):1270-6 [11743050.001]
  • [Cites] J Virol. 2002 Mar;76(6):3072-7 [11861876.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):567-72 [11920617.001]
  • [Cites] Br J Haematol. 2002 Jul;118(1):195-201 [12100148.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):665-72 [12115499.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):463-71 [12450732.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):601-5 [12684696.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jan;26(1):72-3 [14707720.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):83-92 [15327980.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 24;322(3):1052-8 [15336571.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Histopathology. 1992 Jul;21(1):51-7 [1321787.001]
  • [Cites] Mol Cell Probes. 1993 Apr;7(2):105-9 [8391639.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1493-501 [7632957.001]
  • [Cites] Immunol Rev. 2006 Aug;212:86-98 [16903908.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2280-9 [16757686.001]
  • (PMID = 18502823.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL20 protein, human; 0 / Chemokine CCL20; 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens
  • [Other-IDs] NLM/ PMC2438297
  •  go-up   go-down


37. Mordukhovich I, Rossner P Jr, Terry MB, Santella R, Zhang YJ, Hibshoosh H, Memeo L, Mansukhani M, Long CM, Garbowski G, Agrawal M, Gaudet MM, Steck SE, Sagiv SK, Eng SM, Teitelbaum SL, Neugut AI, Conway-Dorsey K, Gammon MD: Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors. Environ Health Perspect; 2010 Apr;118(4):511-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associations between polycyclic aromatic hydrocarbon-related exposures and p53 mutations in breast tumors.
  • Certain carcinogens may be associated with specific mutation patterns in the p53 tumor suppressor gene, thereby contributing information about disease etiology.
  • OBJECTIVES: We hypothesized that associations of PAH-related exposures with breast cancer would differ according to tumor p53 mutation status, effect, type, and number.
  • As previously reported, 151 p53 mutations among 859 tumors were identified using Surveyor nuclease and confirmed by sequencing.
  • CONCLUSIONS: These findings suggest that PAHs may be associated with specific breast tumor p53 mutation subgroups rather than with overall p53 mutations and may also be related to breast cancer through mechanisms other than p53 mutation.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biomarkers. 2002 May-Jun;7(3):209-29 [12141065.001]
  • [Cites] J Cell Mol Med. 2009 Sep;13(9B):3847-57 [19602056.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jun;74(3):235-54 [12206514.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):829-35 [12223426.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):953-71 [12376493.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):221-7 [12569578.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):565-71 [12663519.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7530-8 [14612556.001]
  • [Cites] Biotechniques. 2004 Apr;36(4):702-7 [15088388.001]
  • [Cites] Environ Res. 2004 Oct;96(2):176-85 [15325878.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):1945-9 [7043469.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] Toxicol Ind Health. 1990 Mar;6(2):209-23 [2356563.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18 Suppl):5023s-5044s [1884379.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1013-7 [8430068.001]
  • [Cites] Mutagenesis. 1993 Jul;8(4):275-83 [8377645.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] Carcinogenesis. 1995 Feb;16(2):431-4 [7859378.001]
  • [Cites] Am J Epidemiol. 1996 Nov 15;144(10):924-33 [8916503.001]
  • [Cites] Carcinogenesis. 2000 Jul;21(7):1281-9 [10874004.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1764-72 [11058619.001]
  • [Cites] Inhal Toxicol. 2000 Dec;12(12):1173-83 [11114787.001]
  • [Cites] Food Chem Toxicol. 2001 May;39(5):423-36 [11313108.001]
  • [Cites] Breast Cancer. 2001;8(2):98-104 [11342981.001]
  • [Cites] Environ Mol Mutagen. 2002;39(2-3):119-26 [11921179.001]
  • [Cites] Environ Mol Mutagen. 2002;39(2-3):254-63 [11921196.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1987-95 [11929815.001]
  • [Cites] Trends Biotechnol. 2002 Jun;20(6):243-8 [12007492.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):997-1003 [8959323.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Biochemistry. 1997 Aug 19;36(33):10256-61 [9254624.001]
  • [Cites] Chemosphere. 1997 Feb;34(4):835-48 [9569946.001]
  • [Cites] In Vivo. 1998 Jan-Feb;12(1):43-8 [9575425.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 18;90(22):1724-9 [9827527.001]
  • [Cites] Mutat Res. 1999 Mar 8;424(1-2):207-19 [10064862.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):255-63 [10090304.001]
  • [Cites] Mutat Res. 1999 Jul 15;443(1-2):139-47 [10415437.001]
  • [Cites] Environ Health Perspect. 1999 Sep;107(9):721-6 [10464072.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):733-9 [10498391.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):53-60 [15668476.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):46-52 [15850004.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2005 Nov;15(6):482-90 [15856074.001]
  • [Cites] J Pathol. 2006 Jan;208(1):1-6 [16331594.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15 [16368942.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):80-5 [16434591.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):602-11 [16614098.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):293-325 [16728565.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):985-91 [16570275.001]
  • [Cites] Arch Environ Health. 2004 Dec;59(12):640-9 [16789472.001]
  • [Cites] Breast Dis. 2005-2006;23:9-15 [16823162.001]
  • [Cites] Pharmacogenomics. 2006 Sep;7(6):935-42 [16981851.001]
  • [Cites] Epidemiology. 2007 May;18(3):373-82 [17435448.001]
  • [Cites] Mutat Res. 2007 Jul 1;620(1-2):71-82 [17434188.001]
  • [Cites] Ann Clin Biochem. 2007 Nov;44(Pt 6):557-9 [17961311.001]
  • [Cites] Int J Gastrointest Cancer. 2006;37(4):139-45 [18049799.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):15-26 [18187392.001]
  • [Cites] Mol Carcinog. 2008 Feb;47(2):88-99 [17683074.001]
  • [Cites] Eur J Cancer. 2008 Mar;44(5):636-40 [18314326.001]
  • [Cites] BMC Med Res Methodol. 2008;8:70 [18973665.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):677-85 [12163319.001]
  • (PMID = 20064791.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / T32 CA009330; United States / NIEHS NIH HHS / ES / P30ES009089; United States / NCI NIH HHS / CA / U01 CA/ES66572; United States / NCI NIH HHS / CA / T32-CA09330; United States / NIEHS NIH HHS / ES / P30ES10126; United States / NIEHS NIH HHS / ES / P30 ES009089
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Adducts; 0 / Polycyclic Hydrocarbons, Aromatic; 0 / Tumor Suppressor Protein p53; 0 / polycyclic aromatic hydrocarbons-DNA adduct
  • [Other-IDs] NLM/ PMC2854728
  •  go-up   go-down


38. Perrault SD, Chan WC: In vivo assembly of nanoparticle components to improve targeted cancer imaging. Proc Natl Acad Sci U S A; 2010 Jun 22;107(25):11194-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using nanoparticles as carriers can improve this because their large size reduces clearance and improves retention within tumors, but it also slows their rate of transfer from circulation into the tumor interstitium.
  • Here, we demonstrate an alternative strategy whereby a molecular contrast agent and engineered nanoparticle undergo in vivo molecular assembly within tumors, combining the rapid influx of the smaller and high retention of the larger component.
  • This strategy provided rapid tumor accumulation of a fluorescent contrast agent, 16- and 8-fold faster than fluorescently labeled macromolecule or nanoparticle controls achieved.
  • The advantage of the in vivo assembly approach for targeting is rapid accumulation of small molecular agents in tumors, shorter circulation time requirements, possible systemic clearance while maintaining imaging sensitivity in the tumor, and nanoparticle anchors in tumors can be utilized to alter the pharmacokinetics of contrast agents, therapeutics, and other nanoparticles.
  • This study demonstrates molecular assembly of nanoparticles within tumors, and provides a new basis for the future design of nanomaterials for medical applications.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 1993 Sep;34(9):1552-64 [8355076.001]
  • [Cites] Nucl Med Commun. 1988 Nov;9(11):931-41 [3251178.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3752-6 [7641188.001]
  • [Cites] Nucl Med Biol. 1996 May;23(4):459-66 [8832700.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 [9539785.001]
  • [Cites] Eur J Nucl Med. 1999 Apr;26(4):348-57 [10199940.001]
  • [Cites] Curr Opin Biotechnol. 2005 Feb;16(1):63-72 [15722017.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):313-20 [15765087.001]
  • [Cites] Eur J Pharm Sci. 2006 Jan;27(1):27-36 [16150582.001]
  • [Cites] Magn Reson Med. 2006 May;55(5):1023-9 [16586449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):932-6 [17215365.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):580-9 [18385732.001]
  • [Cites] Pharm Res. 2009 Jan;26(1):235-43 [18712584.001]
  • [Cites] Nat Rev Drug Discov. 2008 Sep;7(9):771-82 [18758474.001]
  • [Cites] Nano Lett. 2009 May;9(5):1909-15 [19344179.001]
  • [Cites] Anal Chem. 2009 Jun 1;81(11):4560-5 [19408951.001]
  • [Cites] Eur J Radiol. 2009 Jun;70(3):393-400 [19457631.001]
  • [Cites] Nat Nanotechnol. 2010 Jan;5(1):42-7 [19893516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):981-6 [20080556.001]
  • [Cites] Adv Mater. 2010 Feb 23;22(8):880-5 [20217810.001]
  • [Cites] J Cell Biol. 2010 Mar 22;188(6):759-68 [20231381.001]
  • [Cites] FASEB J. 2010 Jun;24(6):1689-99 [20075195.001]
  • [Cites] Annu Rev Biomed Eng. 1999;1:241-63 [11701489.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12617-21 [12235356.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):969-76 [15258594.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2160-5 [8174123.001]
  • (PMID = 20534561.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP:193110; Canada / Canadian Institutes of Health Research / / RMF-7255
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Fluorescent Dyes; 30IQX730WE / Polyethylene Glycols
  • [Other-IDs] NLM/ PMC2895069
  •  go-up   go-down


39. Tawfik O, Kimler BF, Davis M, Stasik C, Lai SM, Mayo MS, Fan F, Donahue JK, Damjanov I, Thomas P, Connor C, Jewell WR, Smith H, Fabian CJ: Grading invasive ductal carcinoma of the breast: advantages of using automated proliferation index instead of mitotic count. Virchows Arch; 2007 Jun;450(6):627-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our objective was to evaluate a new grading system [the nuclear grade plus proliferation (N+P) system] for subjectivity, ease, and better representation of tumor biology.
  • Invasive ductal carcinomas, consisting of 137 SBR grade I, 247 grade II, and 266 grade III, were re-evaluated by the N+P system.
  • The two systems were compared with each other and correlated with patients' overall survival, tumor size, angiolymphatic invasion, lymph node status, and biomarker status including estrogen receptor, progesterone receptor, p53, epidermal growth factor receptor, BCL-2, and Her-2.
  • Although there was an agreement between the two systems with histologic and prognostic parameters studied, there was 37% disagreement when grading individual tumors.
  • Fifty-three percent of SBR grade II tumors were "down-graded" to N+P grade I, and 7% were "up-graded" to N+P grade III.
  • Distinction among the different histologic grades for overall survival curves was better indicated by the N+P than the SBR system.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Cohort Studies. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Middle Aged. Mitotic Index. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Survival Analysis


40. Beljebbar A, Dukic S, Amharref N, Manfait M: Ex vivo and in vivo diagnosis of C6 glioblastoma development by Raman spectroscopy coupled to a microprobe. Anal Bioanal Chem; 2010 Sep;398(1):477-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo and in vivo diagnosis of C6 glioblastoma development by Raman spectroscopy coupled to a microprobe.
  • The potential of Raman spectroscopy for ex vivo and in vivo classification of normal and glioblastoma brain tumor development was investigated.
  • High-quality spectra of normal and tumor tissues were obtained using a portable Raman spectrometer coupled to a microprobe with a signal integration time of 5 s.
  • Ex vivo results demonstrated that by using the biochemical information contained in the spectra, we were able to distinguish between normal brain features (white and gray matter), invasion, and tumor tissues with a classification accuracy of 100%.
  • This finding supports the ability of in vivo Raman spectroscopy to delineate tumor margins during surgery.
  • After implanting C6 cells in rat brain, we monitored, in vivo, the development of glioblastoma tumor from days 0 to 20 post-implantation (PI).
  • The classification exhibited a clear separation of the data into two clusters: one cluster was associated with normal brain tissues (cortex), and the second was related to data measured from tumor evolution.
  • The second cluster could be divided into two subclusters, one associated with tumor tissue from 4 to 13 days PI and the second related to tumor tissue from 15 to 20 days PI.
  • Histological analysis reveals that the differences between these two subclusters are: the presence of a massive infiltration zone in the brain tissue from 4 to 13 days PI, and; a maturation of the tumor characterized by the appearance of edematous and necrotic zones, as well as a diminution in the proliferative and invasive area, from 15 days.
  • This work demonstrates the potential of Raman spectroscopy to provide diagnostic information for the early detection of tumors in vivo.
  • [MeSH-major] Biosensing Techniques / instrumentation. Brain / pathology. Brain Mapping. Brain Neoplasms / diagnosis. Glioblastoma / diagnosis. Spectrum Analysis, Raman


41. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, Rosen B, Minkin S, Squire JA, Macgregor PF: High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia; 2005 Jun;7(6):603-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two to 4 Mb interval arrays were used to map genomic imbalances in 26 sporadic serous ovarian tumors.
  • Gene expression profiles were obtained from a subset of these tumors and identified a group of genes whose differential expression was significantly associated with drug resistance.
  • [MeSH-major] Chromosome Mapping / methods. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics
  • [MeSH-minor] Cell Nucleus / metabolism. DNA / chemistry. Drug Resistance, Neoplasm. Epithelial Cells / cytology. Female. Gene Expression Profiling. Genome. Humans. In Situ Hybridization, Fluorescence. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis. RNA / chemistry


42. Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM: Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol; 2007 Dec;1(3):321-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.
  • Recently, we presented evidence--based on the analysis of benign hyperproliferative lesions of the breast--for the presence of cells that express the stem cell marker cytokeratin (CK) 15 in combination with CK19, a protein widely expressed by mammary epithelial cells.
  • Here we report the finding of a subset of breast carcinomas characterized by expression of CK15.
  • CK15 expressing tumors constituted 5% (6 out of 120; 4 of ductal type and 2 of lobular type) of the high-risk breast carcinomas examined by gel-based proteomics and immunohistochemistry.
  • The remaining tumor was mainly composed of cells expressing both CK15 and CK19 (CK15+/CK19+), but it also contained invasive areas with cells expressing only one of these makers (CK15+/CK19- and CK15-/CK19+ cells).
  • To address the relationship between putative luminal progenitor/amplified CK15+ cells and malignant disease, and to determine whether cells/lesions lose expression of CK15 as a result of tumour initiation and/or progression, we searched among our sample set for carcinomas in which invasive tumor areas co-existed with non-malignant cells and hyperproliferative and known pre-malignant lesions.
  • Only one such tumour was found (T71), a CK15-/CK19+/p53+ carcinoma that contained p53 negative non-malignant epithelial cells exhibiting a variety of, CK15/CK19 cellular phenotypes (CK15+/CK19+; CK15+/CK19-; CK15-/CK19+; CK15-/CK19-), often associated with simple columnar cells.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Keratin-15 / metabolism. Precancerous Conditions / pathology. Stem Cells
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness


43. Frentzen A, Yu YA, Chen N, Zhang Q, Weibel S, Raab V, Szalay AA: Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A; 2009 Aug 4;106(31):12915-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Successful tumor-specific delivery and continued production of functional scAb derived from individual VACV strains were obtained in tumor xenografts following a single intravenous injection of the virus.
  • The VACV strains expressing the scAb exhibited significantly enhanced therapeutic efficacy in comparison to treatment of human tumor xenografts with the parental virus GLV-1h68.
  • This enhanced efficacy was comparable to the concomitant treatment of tumors with a one-time i.v. injection of GLV-1h68 and multiple i.p. injections of Avastin.
  • Taken together, the VACV-mediated delivery and production of immunotherapeutic anti-VEGF scAb in colonized tumors may open the way for a unique therapy concept: tumor-specific, locally amplified drug therapy in humans.
  • [MeSH-major] Antibodies / genetics. Neoplasms, Experimental / therapy. Oncolytic Virotherapy. Oncolytic Viruses / genetics. Vaccinia virus / genetics. Vascular Endothelial Growth Factor A / immunology
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Bevacizumab. Cell Line. Cercopithecus aethiops. Female. Humans. Male. Mice. Neoplasm Transplantation. Transplantation, Heterologous. Virus Replication

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(6):964-72 [12879198.001]
  • [Cites] Virology. 1962 Sep;18:9-18 [14036977.001]
  • [Cites] Cancer Immunol Immunother. 1987;25(1):7-9 [3594492.001]
  • [Cites] J Natl Cancer Inst. 1989 Apr 19;81(8):570-6 [2649688.001]
  • [Cites] J Virol. 1990 Jun;64(6):3108-11 [2159565.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Gene. 1994 May 16;142(2):259-63 [8194761.001]
  • [Cites] Clin Pharmacokinet. 1995 Feb;28(2):126-42 [7736688.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8 [8876137.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1903-12 [15937544.001]
  • [Cites] Curr Gene Ther. 2005 Aug;5(4):429-43 [16101516.001]
  • [Cites] EXS. 2006;(96):223-68 [16383021.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Histol Histopathol. 2006 Oct;21(10):1125-34 [16835835.001]
  • [Cites] Bioessays. 2007 Nov;29(11):1159-68 [17935210.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):10038-46 [17942938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17069-74 [17942672.001]
  • [Cites] Cell. 2007 Nov 2;131(3):463-75 [17981115.001]
  • [Cites] Surgery. 2007 Dec;142(6):976-83; discussion 976-83 [18063085.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71 [18221053.001]
  • [Cites] Lancet. 2008 Mar 1;371(9614):771-83 [18275997.001]
  • [Cites] N Engl J Med. 2008 May 8;358(19):2039-49 [18463380.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 May;8(5):689-99 [18471042.001]
  • [Cites] Cell Microbiol. 2008 Jun;10(6):1235-48 [18208564.001]
  • [Cites] Hum Gene Ther. 2008 Aug;19(8):774-82 [18754710.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11):4403-7 [18697871.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):141-51 [19139123.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2963-70 [10537366.001]
  • [Cites] Int Immunol. 2000 May;12(5):671-6 [10784613.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6253-8 [11103779.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):149-68 [11259838.001]
  • [Cites] Biotechniques. 1997 Dec;23(6):1094-7 [9421642.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):821-6 [9816236.001]
  • [Cites] Minerva Med. 1999 Jan-Feb;90(1-2):15-23 [10388459.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3396-403 [10416601.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • (PMID = 19617539.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2722284
  •  go-up   go-down


44. Rudmik LR, Buie WD, Heine JA: Reoperation for intraluminal rectal cancer recurrence. Dis Colon Rectum; 2005 Sep;48(9):1752-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Following curative resection for rectal cancer, approximately 5 percent of locoregional recurrences occur intraluminally, presumably because of tumor exfoliation during the initial operation.
  • RESULTS: Initial procedures performed were four high anterior resections and five low anterior resections for tumors having a median distance from the anal verge of 12.5 (range, 7.5-16) cm.
  • Original tumor staging was T2 N0 M0 in three, T3 N0 M0 in three, T3 N1 M0 in one, and T3 N2 M0 in two.
  • Six of nine patients are alive and disease-free with a median follow-up of 34.5 (range, 6-59) months.
  • One patient died disease-free at 35 months.
  • CONCLUSION: Endoscopic surveillance following sphincter-sparing rectal cancer resection is warranted as re-resection for intraluminal recurrence can result in locoregional control and significant disease-free survival.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Anastomosis, Surgical / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Reoperation. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991062.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U: Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol; 2005 Aug 20;23(24):5644-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The reduction of local recurrence rates was observed at all tumor heights, although it was not statistically significant for tumors greater than 10 cm from the anal verge.
  • [MeSH-major] Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Preoperative Care. Registries. Statistics, Nonparametric. Survival Rate. Sweden. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110023.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Pedchenko TV, Gonzalez AL, Wang D, DuBois RN, Massion PP: Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol; 2008 Dec;39(6):689-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the differential expression level and localization of PPARbeta/delta in tumors and adjacent normal lung tissue, and the effect of PPARbeta/delta activation on lung cancer cell proliferation and apoptosis.
  • PPARbeta/delta was expressed in all studied human non-small cell lung cancers, and strong PPARbeta/delta immunoreactivity was observed in epithelial cells of more than 75% of studied lung tumors.
  • PPARbeta/delta expression was consistently limited to the cancer cells in tumor tissue, while in adjacent normal lung tissue it was limited predominantly to the mononuclear cells.
  • [MeSH-major] Lung Neoplasms / metabolism. PPAR delta / metabolism. PPAR-beta / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Cell Adhesion. Cell Line, Tumor. Cell Proliferation. Cell Survival. Cyclooxygenase 2 / metabolism. Female. Humans. Immunohistochemistry. Ligands. Lung / metabolism. Lung / pathology. Male. Middle Aged. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46260-7 [11551955.001]
  • [Cites] Anticancer Drugs. 2007 Sep;18(8):861-74 [17667591.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):21341-5 [11927585.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):721-33 [12419217.001]
  • [Cites] Bioorg Med Chem Lett. 2003 May 5;13(9):1517-21 [12699745.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1748-51 [12702555.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 22;308(2):361-8 [12901877.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):267-73 [12943712.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7113-21 [14612504.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):61-70 [14708026.001]
  • [Cites] Cell. 1999 Oct 29;99(3):335-45 [10555149.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13275-80 [11087869.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):78-83 [11148691.001]
  • [Cites] Neoplasia. 2000 Nov-Dec;2(6):483-90 [11228540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5306-11 [11309497.001]
  • [Cites] Oncogene. 2001 Oct 18;20(47):6910-9 [11687970.001]
  • [Cites] Nat Med. 2004 Mar;10(3):245-7 [14758356.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3162-70 [15126355.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Aug;130(8):429-44 [15205946.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):285-95 [15380519.001]
  • [Cites] Biochem J. 1998 Apr 1;331 ( Pt 1):299-308 [9512493.001]
  • [Cites] Curr Biol. 1999 Apr 22;9(8):393-404 [10226025.001]
  • [Cites] J Biol Chem. 2005 Mar 11;280(10):9519-27 [15632134.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):11-7 [15890232.001]
  • [Cites] FEBS Lett. 2005 Jul 4;579(17):3829-36 [15978581.001]
  • [Cites] Anal Biochem. 2005 Sep 1;344(1):8-15 [16038868.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33240-9 [16061473.001]
  • [Cites] Cell Signal. 2006 Jan;18(1):9-20 [16109478.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4394-401 [16618765.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):889-95 [16969348.001]
  • [Cites] Oncogene. 2006 Oct 12;25(47):6239-51 [16702954.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):33982-96 [16966336.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19069-74 [17148604.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):2029-38 [17604333.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3282-8 [12036946.001]
  • (PMID = 18566335.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK062112; United States / NIDDK NIH HHS / DK / R01 DK062112-10; United States / NIDDK NIH HHS / DK / R37 DK047297
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / PPAR delta; 0 / PPAR-beta; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC3159083
  •  go-up   go-down


47. Wehbe K, Pinneau R, Moenner M, Déléris G, Petibois C: FT-IR spectral imaging of blood vessels reveals protein secondary structure deviations induced by tumor growth. Anal Bioanal Chem; 2008 Sep;392(1-2):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FT-IR spectral imaging of blood vessels reveals protein secondary structure deviations induced by tumor growth.
  • Vascular basement membrane remodeling is involved in tumor angiogenesis to enable tumor invasion and growth.
  • FT-IR spectral imaging was used to determine changes in tumor blood vessels to reveal protein secondary structure in Rag-gamma immuno-deficient mice sacrificed 14 and 21 days after subcutaneous glioma implantation.
  • For the oldest blood capillaries (diameter >20 microns), tumor growth induced a decrease in triple-helix content (1638 cm(-1); -7.3%; P < 0.05) and an increase in beta turns (1666 and 1615 cm(-1); +4%; P < 0.01).
  • These protein-structure alterations, mainly from type IV collagen, reflected the high angiogenic stress of growing tumors.
  • We propose to use these molecular markers of vascular basement membrane protein alterations for gradation of solid tumors by FT-IR spectral imaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18636246.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Membrane Proteins
  •  go-up   go-down


48. Liu GY, Luo Q, Xiong B, Pan C, Yin P, Liao HF, Zhuang WC, Gao HZ: Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors. World J Gastroenterol; 2008 Dec 21;14(47):7199-207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors.
  • AIM: To rapidly detect molecular alterations in different malignancies and investigate the possible role of Tp53, C-myc, and CCND1 genes in development of tumors in human organs and their adjacent normal tissues, as well as the possible relation between well- and poorly-differentiated tumors.
  • METHODS: A tissue array consisting of seven different tumors was generated.
  • [MeSH-major] Cyclin D1 / metabolism. Esophageal Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Proto-Oncogene Proteins c-myc / metabolism. Stomach Neoplasms / metabolism. Tissue Array Analysis. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Breast Neoplasms / ethnology. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. China. Colonic Neoplasms / ethnology. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Humans. Liver Neoplasms / ethnology. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. RNA, Messenger / metabolism. Rectal Neoplasms / ethnology. Rectal Neoplasms / genetics. Rectal Neoplasms / metabolism. Thyroid Neoplasms / ethnology. Thyroid Neoplasms / genetics. Thyroid Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 May 1;57(9):1769-75 [9135021.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Lung Cancer. 2001 Nov;34(2):207-18 [11679179.001]
  • [Cites] Breast Cancer Res Treat. 2002 Jul;74(1):25-31 [12150449.001]
  • [Cites] Mol Cell Biol. 1984 Feb;4(2):276-81 [6366518.001]
  • [Cites] Lab Invest. 1986 Aug;55(2):244-8 [3525985.001]
  • [Cites] Mol Cell Biol. 1985 Oct;5(10):2851-5 [3915536.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8403-7 [2236048.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5006-10 [2052583.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8237-41 [1896475.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):545-50 [1519662.001]
  • [Cites] Anal Biochem. 1993 Nov 15;215(1):86-9 [7507651.001]
  • [Cites] Am J Clin Pathol. 1994 Nov;102(5):695-8 [7942638.001]
  • [Cites] J Cell Biochem Suppl. 1996;25:23-8 [9027594.001]
  • [Cites] Cell. 1997 Feb 7;88(3):405-15 [9039267.001]
  • [Cites] J Pathol. 1997 Mar;181(3):267-9 [9155710.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 May;123(5):497-502 [9158396.001]
  • [Cites] Br J Cancer. 1997;76(1):21-8 [9218727.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Br J Plast Surg. 1998 Apr;51(3):191-4 [9664877.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):259-62 [15668280.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):637-46 [15612024.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nat Methods. 2006 Jan;3(1):27-9 [16369549.001]
  • [Cites] RNA. 2006 May;12(5):913-20 [16540696.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1688-95 [11104567.001]
  • (PMID = 19084934.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2776877
  •  go-up   go-down


49. Ho-Yen C, Chang F, van der Walt J, Lucas S: Gastrointestinal malignancies in HIV-infected or immunosuppressed patients: pathologic features and review of the literature. Adv Anat Pathol; 2007 Nov;14(6):431-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several other malignancies that occur in the GI tract are also closely related to HIV-infected or immunosuppressed individuals; these include posttransplant lymphoproliferative disorder, Epstein-Barr virus-associated smooth muscle tumors, anal precancerous lesions, and squamous cell carcinoma.
  • Therefore, it is possible that the number of AIDS-associated malignancies will rise and the pattern of tumors may change in the future.
  • In this paper, the clinicopathologic features of GI malignancies associated with AIDS patients are reviewed and the differential diagnosis with other mimic lesions is discussed.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Gastrointestinal Neoplasms / pathology. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / pathology. Sarcoma, Kaposi / pathology


50. Draper JM, Smith CD: DHHC20: a human palmitoyl acyltransferase that causes cellular transformation. Mol Membr Biol; 2010 Apr;27(2-3):123-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compared with control cells, cells overexpressing wild-type DHHC20 displayed an increase in palmitoylation activity toward a peptide that mimics the N-terminus of myristoylated and palmitoylated proteins, but had no change in activity toward a peptide that mimics the C-terminus of farnesylated and palmitoylated proteins.
  • Quantitative polymerase chain reaction analyses of human tissues demonstrated that DHHC20 is expressed in a tissue-specific manner, and is overexpressed in several types of human tumors, including ovarian, breast and prostate.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Naturwissenschaften. 2002 Sep;89(9):381-90 [12435088.001]
  • [Cites] J Biol Chem. 2002 Oct 25;277(43):41268-73 [12193598.001]
  • [Cites] Biochem J. 2003 Jul 1;373(Pt 1):91-9 [12670300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7071-5 [6594680.001]
  • [Cites] Oncogene Res. 1987 Sep-Oct;1(4):357-74 [2835736.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1167-77 [2661017.001]
  • [Cites] Cell. 1991 Jul 26;66(2):327-34 [1855253.001]
  • [Cites] Science. 1993 Jun 25;260(5116):1934-7 [8316833.001]
  • [Cites] Oncogene. 1993 Oct;8(10):2627-35 [7690925.001]
  • [Cites] Trends Biochem Sci. 1995 May;20(5):181-7 [7610481.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11541-7 [8626715.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):7154-9 [8636152.001]
  • [Cites] J Cell Biol. 1996 Aug;134(3):647-60 [8707845.001]
  • [Cites] J Biol Chem. 1996 Sep 20;271(38):23269-76 [8798525.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1401-7 [8869106.001]
  • [Cites] Cell Signal. 1996 Sep;8(6):403-12 [8958442.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):148-54 [9069258.001]
  • [Cites] J Med Chem. 1997 Sep 12;40(19):2971-90 [9301658.001]
  • [Cites] Annu Rev Cell Dev Biol. 1997;13:513-609 [9442882.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1397-404 [9816313.001]
  • [Cites] Biochim Biophys Acta. 1999 Aug 12;1451(1):1-16 [10446384.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9230-7 [15489887.001]
  • [Cites] Neuron. 2004 Dec 16;44(6):987-96 [15603741.001]
  • [Cites] EMBO J. 2005 Jul 20;24(14):2524-32 [15973437.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31141-8 [16000296.001]
  • [Cites] J Cell Biol. 2005 Sep 26;170(7):1091-9 [16186255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17366-71 [16301533.001]
  • [Cites] Mol Cancer Res. 2006 Jan;4(1):39-45 [16446405.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1761(4):474-83 [16647879.001]
  • [Cites] J Cell Biol. 2006 Jul 31;174(3):369-77 [16864653.001]
  • [Cites] Mol Cancer Ther. 2006 Jul;5(7):1647-59 [16891450.001]
  • [Cites] Nat Chem Biol. 2006 Oct;2(10):518-28 [16983387.001]
  • [Cites] J Biol Chem. 2006 Oct 13;281(41):30907-16 [16912036.001]
  • [Cites] Sci STKE. 2006 Oct 31;2006(359):re14 [17077383.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1764(12):1914-31 [17110180.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jan;8(1):74-84 [17183362.001]
  • [Cites] Biophys J. 2007 Feb 1;92(3):808-15 [17098795.001]
  • [Cites] J Cell Biol. 2007 Jan 29;176(3):249-54 [17242068.001]
  • [Cites] Oncogene. 2007 Mar 8;26(11):1577-85 [16953222.001]
  • [Cites] J Lipid Res. 2007 Aug;48(8):1873-84 [17525474.001]
  • [Cites] J Cell Sci. 2007 Aug 1;120(Pt 15):2555-64 [17623777.001]
  • [Cites] Oncogene. 2008 May 15;27(22):3194-200 [18071309.001]
  • [Cites] Mol Cell Proteomics. 2008 Jul;7(7):1378-88 [18296695.001]
  • [Cites] Mol Biol Cell. 2008 Aug;19(8):3415-25 [18508921.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22076-88 [18534984.001]
  • [Cites] J Cell Sci. 2009 Mar 15;122(Pt 6):867-74 [19240115.001]
  • [Cites] Immunol Lett. 2001 Mar 1;76(2):133-8 [11274732.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Apr;127(4):226-30 [11315256.001]
  • [Cites] Oncogene. 2001 Mar 22;20(12):1465-75 [11313890.001]
  • [Cites] J Am Chem Soc. 2002 Mar 20;124(11):2444-5 [11890786.001]
  • [Cites] Anal Biochem. 2002 Sep 1;308(1):160-7 [12234477.001]
  • [Cites] J Cell Biol. 2002 Oct 14;159(1):23-8 [12370247.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • (PMID = 20334580.001).
  • [ISSN] 1464-5203
  • [Journal-full-title] Molecular membrane biology
  • [ISO-abbreviation] Mol. Membr. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075248-14; United States / NCI NIH HHS / CA / R01 CA075248; United States / NCI NIH HHS / CA / 2 R01 CA075248; United States / NCI NIH HHS / CA / R01 CA075248-14
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.3.- / Acyltransferases; EC 2.3.- / ZDHHC20 protein, human
  • [Other-IDs] NLM/ NIHMS211989; NLM/ PMC2893407
  •  go-up   go-down


51. Soumarová R, Homola L, Perková H, Czudek S, Skrovina M, Adamcík L: [The role of interstitial brachytherapy in multimodality management of solid tumors]. Rozhl Chir; 2007 Oct;86(10):533-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of interstitial brachytherapy in multimodality management of solid tumors].
  • Its prons include, in particular, a possibility to apply a dose, in addition to external radiotherapy, directly into the tumor region or its focus, which may improve treatment success rates in patients with localized tumors.
  • The commonest diagnoses, where interstitial brachytherapy is employed, include the following: breast carcinomas, soft tissue sarcomas, head and neck tumors, gynaecological tumors, penile and anal tumors and prostate tumors.
  • [MeSH-major] Brachytherapy. Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064791.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 54
  •  go-up   go-down


52. Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Rème T, Bourin P: Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia; 2007 May;21(5):1079-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent literature suggested that cells of the microenvironment of tumors could be abnormal as well.
  • Among the 145 distinct genes differentially expressed in MM and normal BMMSCs, 46% may account for a tumor-microenvironment cross-talk.
  • IL (interleukin)-6, DKK1) were revealed and new ones were found which are involved in angiogenesis, osteogenic differentiation or tumor growth.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13384-9 [11087877.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1953-60 [10961900.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4781-8 [11134143.001]
  • [Cites] Endocrinology. 2001 Mar;142(3):1098-106 [11181524.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1219-30 [11283920.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):14728-36 [11278272.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1950-61 [11753617.001]
  • [Cites] J Immunol. 2002 Jul 15;169(2):642-6 [12097364.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2578-85 [12239172.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4755-63 [12446603.001]
  • [Cites] Bioinformatics. 2002 Dec;18(12):1593-9 [12490443.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):10-7 [12492571.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):8904-12 [12514175.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1521-8 [12707035.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):39-52 [12823344.001]
  • [Cites] Blood. 2003 Jul 15;102(2):592-600 [12663452.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2642-50 [12855642.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):28067-78 [12740383.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:248-78 [14633785.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2495-502 [14695409.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1495-502 [14996910.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2386-92 [15073115.001]
  • [Cites] Anal Biochem. 2004 Jun 1;329(1):77-84 [15136169.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):475-86 [15287939.001]
  • [Cites] Am J Pathol. 2004 Sep;165(3):855-67 [15331410.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6986-90 [15286708.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] Bone. 2004 Aug;35(2):517-24 [15268904.001]
  • [Cites] Blood. 1991 Jun 15;77(12):2688-93 [1675130.001]
  • [Cites] Mol Immunol. 1991 Nov;28(11):1183-92 [1720501.001]
  • [Cites] FEBS Lett. 1993 Nov 8;334(1):41-4 [8224224.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3712-20 [8260708.001]
  • [Cites] Br J Haematol. 1993 Nov;85(3):446-51 [8136264.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3654-63 [8204890.001]
  • [Cites] Leuk Res. 1994 Sep;18(9):675-82 [7934143.001]
  • [Cites] Blood. 1995 Feb 15;85(4):863-72 [7849308.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Blood. 1999 Jan 1;93(1):300-5 [9864174.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1152-60 [9886334.001]
  • [Cites] Cell Tissue Res. 1999 Jul;297(1):103-10 [10398887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10278-83 [10468599.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):57-66 [15720817.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1700-9 [15753365.001]
  • [Cites] Hematology. 2004 Oct-Dec;9(5-6):377-81 [15763977.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2330-6 [15781647.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3512-24 [15735670.001]
  • [Cites] Best Pract Res Clin Haematol. 2005;18(4):653-72 [16026743.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):899-905 [16007089.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3160-5 [16030194.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2953-61 [16540643.001]
  • [Cites] Immunol Rev. 2006 Apr;210:86-104 [16623766.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):986-91 [16293576.001]
  • [Cites] Hum Cell. 2000 Mar;13(1):43-54 [10937346.001]
  • [Cites] Br J Haematol. 2000 Nov;111(2):626-34 [11122111.001]
  • (PMID = 17344918.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / GDF15 protein, human; 0 / Growth Differentiation Factor 15
  • [Other-IDs] NLM/ HALMS270565; NLM/ PMC2346535
  •  go-up   go-down


53. Moshitch-Moshkovitz S, Tsarfaty G, Kaufman DW, Stein GY, Shichrur K, Solomon E, Sigler RH, Resau JH, Vande Woude GF, Tsarfaty I: In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia; 2006 May;8(5):353-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.
  • Approximately 70% of adenocarcinoma tumors metastasized to the kidneys, lungs, or liver.
  • Quantitative subcellular-resolution intravital imaging revealed very high levels of GFP-Met in tumor lesions and in single isolated cells surrounding them, relative to normal sebaceous glands.
  • Higher GFP-Met levels correlated with earlier tumor onset and aggressiveness, further demonstrating the role of Met-HGF/SF signaling in cellular transformation and acquisition of invasive and metastatic phenotypes.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Biol. 2001;2(9):REVIEWS1024 [11574061.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):589-96 [11809714.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1642-7 [11920523.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):289-300 [12001990.001]
  • [Cites] Neoplasia. 2002 Nov-Dec;4(6):510-22 [12407445.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):498-505 [12492492.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7166-9 [12499251.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):231-5 [12539177.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1101-5 [12615728.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):135-41 [12705634.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):112-8 [12708484.001]
  • [Cites] Mol Ther. 2003 Jun;7(6):765-73 [12788650.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6272-81 [14559814.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17198-203 [15557554.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):139-48 [15678502.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6190-7 [16144920.001]
  • [Cites] Oncogene. 2003 Nov 20;22(52):8498-508 [14627990.001]
  • [Cites] Anal Quant Cytol Histol. 1999 Oct;21(5):397-408 [10560522.001]
  • [Cites] FASEB J. 2000 Feb;14(2):319-32 [10657988.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 16;272(3):900-5 [10860849.001]
  • [Cites] Neoplasia. 2000 Jul-Aug;2(4):365-77 [11005571.001]
  • [Cites] Cytometry. 2000 Nov 1;41(3):155-65 [11042611.001]
  • [Cites] Cancer Metastasis Rev. 2000;19(1-2):7-11 [11191066.001]
  • [Cites] Histochem Cell Biol. 2001 Jan;115(1):49-58 [11219608.001]
  • [Cites] J Cell Biol. 2001 May 28;153(5):1023-34 [11381087.001]
  • [Cites] Int J Androl. 2001 Oct;24(5):300-5 [11554988.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25 [14685170.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):202-11 [14734471.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):533-40 [15277227.001]
  • [Cites] Exp Cell Res. 2004 Sep 10;299(1):248-56 [15302591.001]
  • [Cites] Mol Carcinog. 2004 Nov;41(3):150-63 [15390081.001]
  • [Cites] Mol Cell Biol. 1990 Aug;10(8):4406-11 [2164640.001]
  • [Cites] Cancer Metastasis Rev. 1991 Oct;10(3):217-27 [1662559.001]
  • [Cites] Oncogene. 1992 Jun;7(6):1149-57 [1317541.001]
  • [Cites] Mol Cell Biol. 1992 Nov;12(11):5152-8 [1406687.001]
  • [Cites] Acta Pathol Jpn. 1992 Aug;42(8):585-94 [1360186.001]
  • [Cites] Cell Growth Differ. 1993 Jul;4(7):563-9 [8398896.001]
  • [Cites] Science. 1994 Jan 7;263(5143):98-101 [7505952.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1630-3 [8137271.001]
  • [Cites] J Biol Chem. 1994 Apr 29;269(17):12846-51 [8175699.001]
  • [Cites] Cell Growth Differ. 1996 Nov;7(11):1513-23 [8930401.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 [9012848.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):749-60 [9024713.001]
  • [Cites] Nat Genet. 1997 May;16(1):68-73 [9140397.001]
  • [Cites] FEBS Lett. 1997 May 5;407(3):313-9 [9175875.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5391-8 [9393765.001]
  • [Cites] Ophthalmology. 1998 Mar;105(3):497-506 [9499782.001]
  • [Cites] Biochim Biophys Acta. 1998 Feb 11;1395(3):252-8 [9512656.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1513-20 [9554529.001]
  • [Cites] Exp Cell Res. 1998 Oct 10;244(1):367-9 [9770380.001]
  • [Cites] Pathol Int. 1998 Oct;48(10):757-62 [9788258.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5157-67 [9823327.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14417-22 [9826715.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):887-95 [10023664.001]
  • [Cites] Endocr J. 1999 Jun;46(3):359-66 [10503987.001]
  • [Cites] Int J Cancer. 2005 Feb 10;113(4):678-82 [15455388.001]
  • (PMID = 16790084.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA093990; United States / NCI NIH HHS / CA / P50CA93990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 147336-22-9 / Green Fluorescent Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  • [Other-IDs] NLM/ PMC1592452
  •  go-up   go-down


54. Giuffrè M, De Sanctis L: Genetic syndrome suspicion: examples of clinical approach in the neonatal unit. Minerva Pediatr; 2010 Jun;62(3 Suppl 1):199-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within this latter group of diseases, a LGA newborn requires a complex differential diagnosis encompassing several syndromes, such as Beckwith-Wiedemman, Sotos, Weaver, Simpson-Golabi-Behmel, Perlman, and Bannayan-Riley-Ruvalcaba.
  • Partial or global overgrowth, other dysmorphisms, abdominal organs anomalies, as well as benign and malignant tumors are the common issues to examine for the diagnosis and the monitoring of all these disorders.
  • [MeSH-major] Early Diagnosis. Genetic Diseases, Inborn / diagnosis. Genetic Testing. Intensive Care Units, Neonatal. Neonatology / methods
  • [MeSH-minor] Abnormalities, Multiple / diagnosis. Abnormalities, Multiple / genetics. Anal Canal / abnormalities. Birth Weight. Congenital Abnormalities / diagnosis. Congenital Abnormalities / genetics. Esophageal Atresia / diagnosis. Esophageal Atresia / epidemiology. Esophageal Atresia / genetics. Esophagus / abnormalities. Fetal Macrosomia / diagnosis. Fetal Macrosomia / etiology. Heart Defects, Congenital / diagnosis. Heart Defects, Congenital / epidemiology. Heart Defects, Congenital / genetics. Hedgehog Proteins / deficiency. Hedgehog Proteins / genetics. Humans. Infant, Newborn. Kidney / abnormalities. Limb Deformities, Congenital / diagnosis. Limb Deformities, Congenital / epidemiology. Limb Deformities, Congenital / genetics. Patient Care Team. Spine / abnormalities. Syndrome. Trachea / abnormalities

  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21089741.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / SHH protein, human; VACTERL association
  •  go-up   go-down


55. Corner C, Bryant L, Chapman C, Glynne-Jones R, Hoskin PJ: High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy; 2010 Jan-Mar;9(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: High-dose-rate (HDR) intraluminal brachytherapy for advanced or inoperable tumors of the rectum has been used both palliatively and to dose escalate after chemoradiation for curative treatment.
  • METHODS: Between 1993 and 2007, 79 patients were treated with HDR afterloading brachytherapy for rectal cancer; 70 patients had adenocarcinoma of the rectum; and 9 patients had squamous cell carcinoma of the anal canal.
  • Fifty-two patients had localized disease but were unfit for major surgery and received radiotherapy with radical intent.
  • Twenty-seven patients with advanced or metastatic disease received palliative treatment.
  • RESULTS: Objective local tumor response was seen in 41 of 48 assessable patients (85%); of whom, 28 patients (58%) had a complete response and 13 (27%) had a partial response.
  • CONCLUSIONS: Intraluminal HDR brachytherapy is effective as local treatment in both the radical and palliative setting, with high tumor and symptom response rates, and acceptable late toxicity.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Squamous Cell / radiotherapy. Rectal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19846349.001).
  • [ISSN] 1873-1449
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Gandhi M, Dillon LW, Pramanik S, Nikiforov YE, Wang YH: DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene; 2010 Apr 15;29(15):2272-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These rearrangements are commonly associated with radiation exposure; however, most of the tumors found in adults are not linked to radiation.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3477-84 [12067991.001]
  • [Cites] BMC Genomics. 2009;10:59 [19183484.001]
  • [Cites] Cell. 2002 Dec 13;111(6):779-89 [12526805.001]
  • [Cites] Cancer Lett. 2003 Mar 20;192(1):1-17 [12637148.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(20):7143-51 [14517285.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):71-6 [14603443.001]
  • [Cites] Am J Hum Genet. 2004 Oct;75(4):654-60 [15309689.001]
  • [Cites] Science. 1984 Dec 7;226(4679):1199-204 [6239375.001]
  • [Cites] Hum Genet. 1985;69(3):233-7 [2579891.001]
  • [Cites] Hum Genet. 1987 Jan;75(1):75-8 [3100418.001]
  • [Cites] Am J Hum Genet. 1987 Nov;41(5):882-90 [3674017.001]
  • [Cites] Am J Hum Genet. 1988 Sep;43(3):265-73 [3137811.001]
  • [Cites] Hum Genet. 1989 Aug;83(1):45-8 [2504659.001]
  • [Cites] Genet Anal Tech Appl. 1991 Sep;8(6):161-6 [1721827.001]
  • [Cites] Cell. 1995 May 19;81(4):533-40 [7758107.001]
  • [Cites] Nucleic Acids Res. 1995 Oct 25;23(20):4202-9 [7479085.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5617-20 [7585643.001]
  • [Cites] Hum Mol Genet. 1995 Dec;4(12):2313-8 [8634704.001]
  • [Cites] Hum Mol Genet. 1997 Feb;6(2):193-203 [9063739.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4587-92 [9114034.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1690-4 [9135009.001]
  • [Cites] Environ Mol Mutagen. 1997;29(3):250-5 [9142167.001]
  • [Cites] Genomics. 1997 Jun 1;42(2):252-9 [9192845.001]
  • [Cites] Nat Genet. 1997 Nov;17(3):298-304 [9354793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8141-6 [9653154.001]
  • [Cites] Mol Cell. 1998 May;1(6):773-81 [9660961.001]
  • [Cites] Thyroid. 1998 Jun;8(6):485-9 [9669285.001]
  • [Cites] Mol Cell. 1998 Aug;2(2):259-65 [9734364.001]
  • [Cites] Hum Mol Genet. 1999 Mar;8(3):431-7 [9949202.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2364-9 [15671095.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):99-105 [16199894.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):4-12 [16229941.001]
  • [Cites] Oncogene. 1999 Nov 4;18(46):6330-4 [10597232.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1170-5 [10720057.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(12):4420-7 [10825205.001]
  • [Cites] Chromosome Res. 2000;8(8):677-88 [11196131.001]
  • [Cites] Nucleic Acids Res. 2001 Mar 15;29(6):E33 [11239010.001]
  • [Cites] Genomics. 2001 Apr 15;73(2):149-60 [11318605.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1126-35 [16807141.001]
  • [Cites] Eur J Endocrinol. 2006 Nov;155(5):645-53 [17062879.001]
  • [Cites] Mol Cell. 2007 Aug 3;27(3):367-79 [17679088.001]
  • [Cites] J Cell Biochem. 2007 Oct 1;102(2):320-31 [17722107.001]
  • [Cites] Annu Rev Genet. 2007;41:169-92 [17608616.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Jan;8(1):83-95 [18088233.001]
  • [Cites] Cell Res. 2008 Jan;18(1):134-47 [18157161.001]
  • [Cites] Cell Res. 2008 Jan;18(1):114-24 [18166980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):246-51 [18162546.001]
  • [Cites] Mod Pathol. 2008 May;21 Suppl 2:S37-43 [18437172.001]
  • [Cites] Cytogenet Genome Res. 2008;121(3-4):196-200 [18758159.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):89-97 [12086891.001]
  • (PMID = 20101222.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113863-04; United States / NCI NIH HHS / CA / R01 CA113863-04; United States / NCI NIH HHS / CA / CA113863-01A1; United States / NIGMS NIH HHS / GM / T32 GM095440; United States / NCI NIH HHS / CA / R01 CA113863-01A1; United States / NCI NIH HHS / CA / CA113863-03; United States / NCI NIH HHS / CA / R01 CA113863-02; United States / NCI NIH HHS / CA / CA113863-02; United States / NCI NIH HHS / CA / CA113863; United States / NCI NIH HHS / CA / R01 CA113863; United States / NCI NIH HHS / CA / R01 CA113863-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 38966-21-1 / Aphidicolin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
  • [Other-IDs] NLM/ NIHMS166296; NLM/ PMC2855398
  •  go-up   go-down


57. Bolisetty MT, Dy G, Tam W, Beemon KL: Reticuloendotheliosis virus strain T induces miR-155, which targets JARID2 and promotes cell survival. J Virol; 2009 Dec;83(23):12009-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the role of miR-155 in these tumors, we identified JARID2/Jumonji, a cell cycle regulator and part of a histone methyltransferase complex, as a target of miR-155.
  • Further, the overexpression of a sponge complementary to miR-155 in a tumor cell line increased endogenous JARID2 mRNA levels.

  • Genetic Alliance. consumer health - Reticuloendotheliosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 22;18(49):6925-37 [10602467.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5082-9 [17911593.001]
  • [Cites] J Virol. 2000 Dec;74(24):11490-4 [11090145.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] J Virol. 2002 May;76(9):4275-86 [11932393.001]
  • [Cites] J Virol. 2002 Jun;76(11):5581-7 [11991986.001]
  • [Cites] J Virol. 2003 Sep;77(17):9378-87 [12915553.001]
  • [Cites] J Virol. 2003 Dec;77(23):12552-61 [14610178.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2275-86 [14755244.001]
  • [Cites] J Virol. 2004 May;78(10):5139-46 [15113896.001]
  • [Cites] RNA. 2004 Oct;10(10):1507-17 [15383676.001]
  • [Cites] Virology. 1979 Feb;93(1):20-30 [219596.001]
  • [Cites] Cell. 1981 Aug;25(2):421-31 [6269747.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):18952-7 [18024587.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Immunity. 2007 Dec;27(6):847-59 [18055230.001]
  • [Cites] J Biol Chem. 2008 Feb 1;283(5):2654-62 [18048365.001]
  • [Cites] RNA Biol. 2007 Nov;4(3):131-7 [18347435.001]
  • [Cites] J Virol. 2008 Jun;82(11):5295-306 [18367535.001]
  • [Cites] Immunity. 2008 May;28(5):621-9 [18450484.001]
  • [Cites] Immunity. 2008 May;28(5):630-8 [18455451.001]
  • [Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]
  • [Cites] Br J Haematol. 2008 Nov;143(4):570-80 [18950466.001]
  • [Cites] J Virol. 2008 Dec;82(24):12213-20 [18842708.001]
  • [Cites] J Virol. 2009 Jan;83(1):489-92 [18945769.001]
  • [Cites] J Biol Chem. 2009 Jan 9;284(2):733-9 [19010785.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):80-91 [19144316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2735-40 [19193853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7113-8 [19359473.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1374-82 [19520806.001]
  • [Cites] J Virol. 1981 Sep;39(3):713-21 [6270346.001]
  • [Cites] Nature. 1984 Feb 23-29;307(5953):702-8 [6321996.001]
  • [Cites] J Virol. 1984 Oct;52(1):172-82 [6090694.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1126-32 [2999973.001]
  • [Cites] J Biol Chem. 1987 Mar 5;262(7):3422-7 [3029112.001]
  • [Cites] J Virol. 1987 Oct;61(10):3004-12 [3041020.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2657-64 [2548084.001]
  • [Cites] Cell. 1992 Apr 3;69(1):119-28 [1555236.001]
  • [Cites] Avian Dis. 1992 Apr-Jun;36(2):432-9 [1320872.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10962-6 [7971992.001]
  • [Cites] Mol Cell Biol. 1997 Mar;17(3):1490-502 [9032277.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2997-3009 [9566919.001]
  • [Cites] Trends Cell Biol. 1998 May;8(5):202-6 [9695840.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Mol Cell Biol. 1999 Jul;19(7):4672-83 [10373516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] RNA. 2005 Apr;11(4):459-69 [15703439.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7065-70 [16103053.001]
  • [Cites] Cell. 2005 Aug 26;122(4):553-63 [16122423.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):30916-23 [15870077.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Dev Biol. 2007 Mar 15;303(2):549-60 [17189626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5 [17293455.001]
  • [Cites] Science. 2007 Apr 27;316(5824):608-11 [17463290.001]
  • [Cites] RNA. 2007 Jun;13(6):930-6 [17456563.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4944-51 [17327404.001]
  • [Cites] Nat Methods. 2007 Sep;4(9):721-6 [17694064.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5640-3 [11059754.001]
  • (PMID = 19759154.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA124596; United States / NCI NIH HHS / CA / R01 CA124596
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Nerve Tissue Proteins
  • [Other-IDs] NLM/ PMC2786729
  •  go-up   go-down


58. Wang Y, Yu Q, Cho AH, Rondeau G, Welsh J, Adamson E, Mercola D, McClelland M: Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia; 2005 Aug;7(8):748-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of genes that appear to be both differentially methylated and differentially regulated between prostate epithelial and cancer cell lines are novel methylation targets, including PAK6, RAD50, TLX3, PIR51, MAP2K5, INSR, FBN1, and GG2-1, representing a rich new source of candidate genes used to study the role of DNA methylation in prostate tumors.


59. Rocha JJ, Féres O: Transanal endoscopic operation: a new proposal. Acta Cir Bras; 2008;23 Suppl 1:93-104; discussion 104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different techniques for local excision of rectal tumors include: conventional transanal technique, posterior access surgery, therapeutic colonoscopy, transanal endoscopic surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516455.001).
  • [ISSN] 1678-2674
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


60. Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, Shack S, Pearson J, Trissal M, Demeure MJ, Von Hoff DD, Hruby VJ, Gillies RJ, Han H: Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther; 2008 Sep;7(9):3071-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to cooperative binding, multimeric ligands can have high avidity for cells (tumor) expressing all targeting proteins and only show minimal binding to cells (normal tissues) expressing none or only some of the targets.
  • Identifying combinations of targets that concurrently express in tumor cells but not in normal cells is a challenging task.
  • The expression data for genes that encode proteins with cell-surface epitopes were then extracted from the database and analyzed using a novel multivariate rule-based computational approach to identify gene combinations that are expressed at an efficient binding level in tumors but not in normal tissues.
  • These combinations were further ranked according to the proportion of tumor samples that expressed the sets at efficient levels.
  • Protein expression of the genes contained in the top ranked combinations was confirmed using immunohistochemistry on a pancreatic tumor tissue and normal tissue microarrays.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 2001 Oct 1;45(2):83-6 [11590619.001]
  • [Cites] Angew Chem Int Ed Engl. 2008;47(9):1685-8 [18205159.001]
  • [Cites] J Comput Biol. 2002;9(1):105-26 [11911797.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1605-12 [12886250.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 5;14(1):211-5 [14684330.001]
  • [Cites] Anal Chem. 2004 Apr 1;76(7):1817-23 [15053638.001]
  • [Cites] J Am Chem Soc. 2004 May 12;126(18):5730-9 [15125666.001]
  • [Cites] J Cell Biol. 1991 Feb;112(3):385-95 [1991789.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Expert Opin Ther Targets. 2004 Dec;8(6):565-86 [15584863.001]
  • [Cites] J Biol Chem. 2005 Jan 21;280(3):1882-92 [15531581.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:141S-50S [15653662.001]
  • [Cites] Genome Res. 2005 Mar;15(3):443-50 [15741514.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):400-9 [15822916.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Mar;5(2):171-81 [15833047.001]
  • [Cites] Anal Biochem. 2005 Jul 1;342(1):69-77 [15958182.001]
  • [Cites] Expert Rev Proteomics. 2004 Aug;1(2):185-92 [15966813.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]
  • [Cites] Ann Biomed Eng. 2005 Aug;33(8):1113-24 [16133919.001]
  • [Cites] Drug Resist Updat. 2005 Dec;8(6):381-402 [16309948.001]
  • [Cites] J Nucl Med. 2006 May;47(5):763-9 [16644745.001]
  • [Cites] Org Biomol Chem. 2006 May 21;4(10):1958-65 [16688341.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):248-64 [17043623.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3734-44 [17530026.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1256-60 [11888886.001]
  • (PMID = 18765825.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095944-02; United States / NCI NIH HHS / CA / P01 CA109552-039001; United States / NCI NIH HHS / CA / P01 CA109552-049001; United States / NCI NIH HHS / CA / R01 CA097360-04; United States / NCI NIH HHS / CA / P01 CA109552-01A10003; United States / NCI NIH HHS / CA / R33 CA095944-03; United States / NCI NIH HHS / CA / R21 CA095944; United States / NCI NIH HHS / CA / CA109552-03; United States / NCI NIH HHS / CA / CA097360; United States / NCI NIH HHS / CA / CA095944-01; United States / NCI NIH HHS / CA / CA109552-040003; United States / NCI NIH HHS / CA / P01 CA109552-01A17991; United States / NCI NIH HHS / CA / CA109552-01A17991; United States / NCI NIH HHS / CA / CA095944-03; United States / NCI NIH HHS / CA / P01 CA109552-029001; United States / NCI NIH HHS / CA / P01 CA109552-040003; United States / NCI NIH HHS / CA / R01 CA097360; United States / NCI NIH HHS / CA / R33 CA095944-02; United States / NCI NIH HHS / CA / CA097360-01A1; United States / NCI NIH HHS / CA / CA109552-01A19001; United States / NCI NIH HHS / CA / R01 CA097360-03; United States / NCI NIH HHS / CA / CA095944-04; United States / NCI NIH HHS / CA / CA109552-01A10003; United States / NCI NIH HHS / CA / CA109552-01A1; United States / NCI NIH HHS / CA / CA097360-04; United States / NCI NIH HHS / CA / R01 CA097360-01A1; United States / NCI NIH HHS / CA / CA109552-029001; United States / NCI NIH HHS / CA / R21 CA095944-01; United States / NCI NIH HHS / CA / R33 CA095944-04; United States / NCI NIH HHS / CA / P01 CA109552-04; United States / NCI NIH HHS / CA / CA109552-030003; United States / NCI NIH HHS / CA / CA109552-049001; United States / NCI NIH HHS / CA / CA097360-03; United States / NCI NIH HHS / CA / CA109552-039001; United States / NCI NIH HHS / CA / P01 CA109552-01A1; United States / NCI NIH HHS / CA / P01 CA109552-03; United States / NCI NIH HHS / CA / R01 CA097360-02; United States / NCI NIH HHS / CA / CA097360-02; United States / NCI NIH HHS / CA / P01 CA109552-01A19001; United States / NCI NIH HHS / CA / CA109552-020003; United States / NCI NIH HHS / CA / P01 CA109552; United States / NCI NIH HHS / CA / CA109552; United States / NCI NIH HHS / CA / CA095944; United States / NCI NIH HHS / CA / CA109552-02; United States / NCI NIH HHS / CA / CA109552-04; United States / NCI NIH HHS / CA / P01 CA109552-030003; United States / NCI NIH HHS / CA / R01 CA097360-05A1; United States / NCI NIH HHS / CA / P01 CA109552-020003; United States / NCI NIH HHS / CA / R33 CA095944; United States / NCI NIH HHS / CA / P01 CA109552-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands
  • [Other-IDs] NLM/ NIHMS69565; NLM/ PMC2567866
  •  go-up   go-down


61. Stuelten CH, Buck MB, Dippon J, Roberts AB, Fritz P, Knabbe C: Smad4-expression is decreased in breast cancer tissues: a retrospective study. BMC Cancer; 2006;6:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although transforming growth factor beta (TGF-beta) typically inhibits proliferation of epithelial cells, consistent with a tumor suppressor activity, it paradoxically also exhibits pro-metastatic activity in the later stages of carcinogenesis.
  • Since tumors often display altered TGF-beta signaling, particularly involving the Smad-pathway, we investigated the role of Smad4-expression in breast cancer.
  • Smad4-expression correlated positively with expression of TGF-beta-receptor I (p < 0.001, n = 197) and TGF-beta-receptor II (p < 0.001, n = 197), but showed no significant correlation with tumor size, metastases, nodal status, histological grade, histological type, or estrogen receptor expression.
  • While not achieving statistical significance, there was a trend towards longer survival times in patients with Smad4 negative tumors.
  • CONCLUSION: According to the suggested role of Smad4 as a tumor suppressor we observed that expression of Smad4 is lower in human breast cancer than in surrounding breast epithelium.
  • However, we also observed a trend towards longer survival times in Smad4-negative patients, indicating the complex role of TGF-beta signaling in tumor progression.
  • [MeSH-major] Breast Neoplasms / chemistry. Smad4 Protein / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / chemistry. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis. Receptors, Estrogen / analysis. Receptors, Transforming Growth Factor beta / analysis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999;10 Suppl 4:56-9 [10436786.001]
  • [Cites] EMBO J. 1998 Jul 15;17(14):4056-65 [9670020.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1427-32 [9990040.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):37-43 [10623651.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4820-5 [10781087.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 16;272(3):705-11 [10860819.001]
  • [Cites] Int J Cancer. 2001 Jan 1;91(1):76-82 [11149423.001]
  • [Cites] Breast Cancer Res. 2000;2(5):331-4 [11250725.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Apr;23(2):109-17 [11332076.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23 [11535541.001]
  • [Cites] J Biol Chem. 2001 Nov 16;276(46):42908-14 [11555647.001]
  • [Cites] J Endocrinol. 2002 Jan;172(1):187-98 [11786386.001]
  • [Cites] Curr Opin Genet Dev. 2002 Feb;12(1):22-9 [11790550.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):497-505 [11809701.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):96-103 [11818142.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1838-42 [12060625.001]
  • [Cites] Gut. 2002 Jul;51(1):56-9 [12077092.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):277-81 [12543773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8430-5 [12808151.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):27853-63 [12740389.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):31043-8 [12813045.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33571-82 [12794086.001]
  • [Cites] J Clin Invest. 2003 Oct;112(7):1116-24 [14523048.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8284-92 [14678987.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):491-8 [14760070.001]
  • [Cites] Mod Pathol. 2004 Jul;17(7):756-64 [15073601.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4523-30 [15231662.001]
  • [Cites] Cell. 1987 Feb 13;48(3):417-28 [2879636.001]
  • [Cites] Pathologe. 1987 May;8(3):138-40 [3303008.001]
  • [Cites] J Cell Physiol. 1989 Nov;141(2):353-61 [2808542.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Am J Clin Oncol. 1991;14 Suppl 2:S15-20 [1835818.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6949-52 [1458485.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):736-42 [8314352.001]
  • [Cites] Trends Biochem Sci. 1994 Dec;19(12):548-53 [7846768.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Oncogene. 1997 Apr 24;14(16):1891-9 [9150356.001]
  • [Cites] Nature. 1997 Dec 4;390(6659):465-71 [9393997.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13909-14 [16172383.001]
  • (PMID = 16438724.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Transforming Growth Factor beta; 0 / SMAD4 protein, human; 0 / Smad4 Protein
  • [Other-IDs] NLM/ PMC1413545
  •  go-up   go-down


62. Gebhart E: Double minutes, cytogenetic equivalents of gene amplification, in human neoplasia - a review. Clin Transl Oncol; 2005 Dec;7(11):477-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double minutes, cytogenetic equivalents of gene amplification, in human neoplasia - a review.
  • Double minutes are tiny spherical chromatin bodies of a few mega-base pairs of size which are found occasionally in hematopoietic neoplasia and more or less often in human solid tumors.
  • The identification of involved chromosomal segments and their molecular nature led to the development of molecular genetic techniques for a rapid and reliable detection of prognostically important oncogene amplifications in human tumors and,as a consequence, to gene-targeted therapy.
  • [MeSH-major] Chromatin / ultrastructure. DNA, Neoplasm / genetics. Gene Amplification. Neoplasms / genetics
  • [MeSH-minor] Drug Resistance, Neoplasm / genetics. Hematologic Neoplasms / genetics. Hematologic Neoplasms / pathology. Humans. Neoplasm Proteins / genetics. Oncogenes. Polymerase Chain Reaction. Prognosis. Tetrahydrofolate Dehydrogenase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 1997 Aug;21(8):703-9 [9379677.001]
  • [Cites] Eur J Cancer. 1995;31A(4):520-3 [7576957.001]
  • [Cites] Br J Haematol. 1995 Jun;90(2):486-8 [7540858.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Nov;155(1):1-24 [15527898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11368-73 [15269346.001]
  • [Cites] Anticancer Res. 1993 Jan-Feb;13(1):113-8 [8476201.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Nov;20(3):243-52 [9365831.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Oct;32(2):126-35 [11550280.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Oct 15;154(2):124-30 [15474147.001]
  • [Cites] Pathol Oncol Res. 1997;3(1):3-7 [11173617.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):26-33 [11343775.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Jan;30(1):73-82 [3275490.001]
  • [Cites] J Biol Chem. 1979 Sep 10;254(17):8679-89 [381311.001]
  • [Cites] Cancer Genet Cytogenet. 1997 May;95(1):20-32 [9140450.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Aug;145(1):1-30 [12885459.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Nov;8(3):185-9 [7509627.001]
  • [Cites] Chromosoma. 1988 Nov;97(3):198-203 [3219916.001]
  • [Cites] Hereditas. 1978;88(1):81-92 [649427.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):55-9 [1728951.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1579-84 [11337354.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Aug;90(1):70-4 [8780751.001]
  • [Cites] Am J Hematol. 2004 Sep;77(1):55-61 [15307107.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1322-8 [1346589.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):406-12 [12619165.001]
  • [Cites] Mutat Res. 2000 Mar 14;448(1):81-90 [10751625.001]
  • [Cites] Blood Cells Mol Dis. 2002 Jul-Aug;29(1):1-13 [12482398.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jan 15;132(2):161-4 [11850082.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2587-95 [11352950.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Dec;71(2):125-31 [8281515.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Apr;27(4):380-6 [10719368.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Nov;75(11):5553-6 [281704.001]
  • [Cites] Int J Cancer. 2004 Apr 10;109 (3):363-9 [14961574.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):10-5 [15325088.001]